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Abstract 
 Diabetic neuropathy is a principal chronic complication of both type 1 and type 2 
diabetes and affects over half of diabetic patients. This debilitating disease presents with a 
dichotomous phenotype such that affected patients can experience both negative and positive 
sensory symptoms including chronic numbness, altered sensitivity to pain or touch, and impaired 
proprioception. In light of long withstanding evidence that hyperglycemia is the primary cause of 
diabetic neuropathy, evidence from several large clinical studies indicate metabolic defects such 
as a poor lipid profile are linked with neuropathy development and progression, independent of 
glycemic control. Consequently, dyslipidemia has recently been identified as an independent risk 
factor for diabetic neuropathy. 
 The purpose of this body of work was to test the effects of diet and dyslipidemia on the 
development and progression of diabetic neuropathy and identify potential mechanisms 
underlying the pathogenesis of high-fat diet induced neuropathy. Initial studies characterized the 
effects of a high-fat diet on neuropathy progression and phenotype in nondiabetic and 
streptozocin (STZ) induced (type 1 model) diabetic mice. STZ-induced diabetic C57Bl/6 mice 
fed a high-fat diet developed dyslipidemia and a painful neuropathy (mechanical hyperalgesia) 
instead of the insensate neuropathy (mechanical insensitivity) that normally develops in this 
mouse strain. Nondiabetic mice fed the high-fat diet also developed dyslipidemia and mechanical 
hyperalgesia. These findings are particularly important because it suggests that diet may 
modulate diabetic neuropathy phenotype.  
 Second, mitochondrial dysfunction, inflammation, and peripheral nervous system insulin 
resistance were investigated as potential mechanisms underlying the pathogenesis of high-fat diet 
induced painful neuropathy. Results from these studies suggest that none of these mechanisms 
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are driving the robust behavioral phenotype observed in high-fat-fed nondiabetic and 
streptozocin-induced diabetic mice.  
 Finally, exercise ameliorated the detrimental effects of a high-fat diet on body weight, 
circulating glucose and insulin levels, and skeletal muscle insulin resistance. These results 
reinforced the importance of exercise in preventing or reversing symptoms of diabetes. Together, 
these studies provide strong evidence for the influence of lifestyle factors, including diet and 
physical activity, on metabolic defects and neural complications associated with diabetes.    
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Introduction 
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Diabetes Mellitus 
Diabetes mellitus is a chronic metabolic disorder characterized by insufficient production 
or utilization of insulin. Insulin deficiency, resulting in inadequate cellular glucose uptake and 
utilization, causes hyperglycemia, excess urine production, and increased fluid intake, the 
hallmark symptoms of this disease. In 2011, the American Diabetes Association reported that 
25.8 million children and adults in the United States (8.3% of the population) have diabetes 
although one quarter of those affected are undiagnosed cases [1]. The prevalence of diabetes 
continues to increase with 1.9 million new cases of diabetes diagnosed in individuals over 20 
years of age per year [1]. Type 1 diabetes affects only 5-10% of diabetic patients and is caused 
by deficient insulin production due to autoimmune destruction of pancreatic beta cells. Type 2 
diabetes, accounting for 90-95% of diabetic cases, is caused by reduced insulin sensitivity in 
muscle and adipose resulting in impaired glucose uptake in these tissues [1]. Type 1 diabetes is 
typically associated with a younger age of onset while older age, obesity, and physical inactivity 
are associated with and considered risk factors for type 2 diabetes [1].  Both type 1 and type 2 
diabetes are associated with serious complications including heart disease, retinopathy, 
nephropathy, and neuropathy, which can lead to stroke or heart attack, vision loss, kidney failure, 
and limb amputations, respectively. Diabetes and its associated complications have a serious 
economic impact accounting for $116 billion in medical costs and $58 billion in indirect costs 
(disability, work loss, premature mortality) each year [1]. Further illustrating the astronomical 
impact of this disease, diabetes was the 7th leading cause of mortality in the United States in 
2007 [2]. 
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Diabetic Neuropathy  
 Diabetic neuropathy is the most common and debilitating complication of both type 1 and 
type 2 diabetes and encompasses several neuropathic syndromes [3]. Diabetic neuropathies can 
be classified into two broad categories: diffuse and focal neuropathies [3, 4]. Diffuse 
neuropathies are more common and typically chronic and progressive in nature while focal 
neuropathies are less common, usually acute in onset, and often self limited [3]. The diffuse 
neuropathies include distal symmetric sensorimotor polyneuropathy and diabetic autonomic 
neuropathy [5].  Distal symmetric sensorimotor polyneuropathy, the most common and widely 
recognized form of diabetic neuropathy, is characterized by both sensory and motor nerve 
deficits; however sensory dysfunction is the predominant feature of this neuropathy [3]. In the 
literature, several names are used interchangeably with distal symmetric sensorimotor 
polyneuropathy, and diabetic peripheral neuropathy is one of the most common synonyms. 
Approximately 70% of diabetic patients will develop peripheral neuropathy [4, 6, 7]. Affected 
patients can experience a large spectrum of sensory symptoms including chronic numbness, 
altered sensitivity to pain or touch, and impaired proprioception [6, 8, 9]. There is no definitive 
cure for this debilitating disease and symptomatic treatments have shown limited success [10].  
This body of work is focused on studying distal symmetric sensorimotor polyneuropathy, which 
will be referred to as diabetic neuropathy from this point forward.    
 Diabetic neuropathy often initially presents as an insensate phenotype that later 
progresses to a painful phenotype [11]. In more advanced stages of this disease, symptoms may 
progress to include motor weakness and impaired proprioception, which can lead to gait 
disturbances and increased risk for falls [4]. Loss of sensation in the extremities frequently leads 
to foot ulcers, thus making diabetic neuropathy the leading cause of amputations [12]. The type 
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of symptoms a patient experiences depends on the type of nerve fibers affected [3]. Large fiber 
disease is associated with impaired proprioception and response to light touch while small fiber 
disease impairs pain and temperature perception [3].  
 
Pathogenesis 
Regardless of the nerve fiber type affected or neuropathy subtype, a dying back-
type distal axon degeneration is the common underlying feature associated with diabetic 
neuropathy [13]. In addition, axon loss may be accompanied by other axonal 
abnormalities including segmental demyelination and reduced nerve regeneration 
capacity [14-16].  It is thought that nerve dysfunction and degeneration leads to 
sensorimotor deficits, reduced nerve conduction velocities, and decreased epidermal 
innervation, all of which are characteristic signs of diabetic neuropathy in human patients 
and animal models [10, 17]. In the setting of diabetes, evidence points to hyperglycemia 
as the initiation factor that leads to a variety of metabolic insults that ultimately damage 
peripheral sensory neurons. Hyperglycemia plays a key role in the development and 
progression of diabetic neuropathy [3, 11, 17-19], and a combination of multiple 
etiologies, each stemming from the initial insult of hyperglycemia, are likely responsible 
for axonal degeneration leading to the various types of neuropathy in diabetic patients [3, 
18, 19]. Hyperglycemia has been shown to lead to oxidative stress, mitochondrial 
dysfunction, increased glucose flux through the polyol pathway, advanced glycation end 
product (AGE) formation [3, 6, 9, 18], disrupted insulin signaling, inflammation, and 
diminished neurotrophic support [20-22]. Each of these mechanisms are currently being 
studied in rodent models of diabetic neuropathy. In addition, dyslipidemia has recently 
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been proposed as an important risk factor that may increase a diabetic patient’s risk of 
developing neuropathy [5, 7, 23]. Despite extensive study of proposed mechanisms, it 
remains unclear why some patients develop insensate versus painful symptoms and how 
underlying pathological mechanisms determine diabetic neuropathy progression and 
phenotype. 
 
Rodent Models of Diabetic Neuropathy 
 Numerous diabetic rodent models have been developed to study diabetic neuropathy. 
Type 1 diabetes is primarily induced in mice or rats by intra-peritoneal injection of streptozocin 
(STZ), a selective pancreatic β-cell toxin. Type 2 diabetic models include genetically obese mice 
due to leptin receptor mutation (db/db) or leptin deficiency (ob/ob). In addition, type 2 diabetes 
is commonly modeled in rodents using high-fat diet-induced obesity.  
 Like human diabetic patients, rodent models display a dichotomous phenotype of diabetic 
neuropathy. Genetic differences are thought to contribute to neuropathy phenotype in rodents, 
but the reason why some rodent models develop painful neuropathy while others develop the 
insensate phenotype remains elusive. Conveniently, rodent models that display variable 
neuropathy phenotypes allow for investigation into mechanisms that underlie symptom 
variability. 
  STZ-induced diabetic rats typically develop mechanical, thermal, and chemical 
hyperalgesia and reduced sensory and motor nerve conduction velocities, but not insensate 
symptoms [10, 24]. STZ-induced diabetic mice exhibit a variety of symptoms that vary based on 
the mouse strain and diabetes duration. Regardless of strain, STZ-diabetic mice typically display 
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sensory and motor nerve conduction velocity deficits and reduced epidermal innervation [10, 
24]; however, STZ-induced C57Bl/6 mice develop mechanical insensitivity while A/J mice 
develop mechanical hyperalgesia.  
 Leptin deficient ob/ob mice, a model of type 2 diabetes, develop thermal hypoalgesia, 
mechanical hyperalgesia, and slowed sensory and motor nerve conduction velocities [25-27]. 
Leptin receptor null mutant mice (db/db) also exhibit deficits in sensory and motor nerve 
conduction velocities [28, 29]. In contrast with the ob/ob strain, db/db mice develop mechanical 
insensitivity without changes in thermal sensation [29].  High-fat fed nondiabetic mice that 
exhibit mechanical hyperalgesia and thermal hypoalgesia are also being utilized to model 
neuropathy in pre-diabetes [5, 23, 30]. It should be noted that the neuronal cell bodies of the 
axons that innervate the lower limbs and hind paws reside in the  lumbar dorsal root ganglia 
(DRG). Thus, the lumbar DRG is an important tissue utilized to examine molecular changes in 
sensory neurons that may affect sensory behavior in rodent models of diabetic neuropathy. 
Although these models are useful for investigating mechanisms underlying the development of 
diabetic neuropathy, none of these models fully emulate the human condition. 
 
Dyslipidemia and Lifestyle Factors 
 Dyslipidemia, typically defined as high serum levels of total cholesterol, low-density 
lipoprotein cholesterol (LDL-C), high triglycerides, and/or low levels of high-density lipoprotein 
cholesterol (HDL-C) [31], has recently been identified as a major independent risk factor that 
increases a diabetic patient’s chances of developing neuropathy [5, 7, 23]. For example, the 
Eurodiab Trial, a longitudinal study of over 3,000 individuals with type 1 diabetes, revealed that 
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dyslipidemia was independently and closely associated with the risk of developing diabetic 
neuropathy during a seven year follow-up period [32]. Importantly, dyslipidemia was associated 
with the onset and progression of neuropathy in both type 1 and type 2 diabetes (reviewed in 
[33]),[34, 35].  
 In addition, other lifestyle factors, such as those that comprise the metabolic syndrome, 
have been associated with neuropathy. The metabolic syndrome is a collection of disorders that 
when occurring together, increase the risk for developing cardiovascular disease and diabetes 
[36]. According to the International Diabetes Federation [36], the consensus worldwide 
definition of the metabolic syndrome is: Central obesity (defined as waist circumference with 
ethnicity specific values) and two of the following: 1) impaired glucose tolerance (fasting 
glucose > 100 mg/dl or diabetes), 2) elevated blood pressure (systolic > 130 or diastolic > 85 mm 
Hg), 3) reduced HDL-C (< 40 mg/dl for women and < 50 mg/dl for men), or 4) elevated 
triglycerides (> 150 mg/dl) or specific treatment for this lipid abnormality. It is noteworthy to 
mention that if body mass index (BMI) is > 30 kg/m2, central obesity can be assumed without 
waist circumference measurement [36]. Nondiabetic patients with idiopathic neuropathy with 
and without impaired glucose tolerance had a significantly higher rate of dyslipidemia and 
hypertension compared to diabetic patients without neuropathy [37]. In addition, the idiopathic 
neuropathy patients had increased prevalence of the metabolic syndrome compared to several 
large population based cohorts [37]. BMI has also been independently associated with the 
incidence of neuropathy in type 1 diabetic subjects [38].  These data suggest that lifestyle factors 
such as obesity, dyslipidemia, and/or hypertension may influence the development neuropathy in 
pre-diabetic and diabetic patients. In addition, elevated circulating lipid levels are associated with 
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insulin resistance and inflammation [39, 40], which have both been suggested as mechanisms 
that contribute to diabetic neuropathy.  
 In support of the clinical evidence, nondiabetic rodents fed a high-fat diet exhibit 
metabolic syndrome parameters including dyslipidemia, hyperinsulinemia, hypertension, 
elevated glucose, and increased body weight in conjunction with painful neuropathy 
characterized by mechanical hyperalgesia, thermal hypoalgesia, demyelination, large myelinated 
and intraepidermal nerve fiber (IENF) loss, and nerve conduction deficits [5, 23, 30, 41]. Vincent 
et al. demonstrated that non-diabetic C57BL/6 mice exhibited impaired glucose tolerance and 
developed neuropathy characterized by reduced sensory and motor nerve conduction velocities, 
sensory deficits, and reduced IENF density after consuming a high-fat diet for 12 weeks [5]. 
Furthermore, this group showed increased oxidative stress markers including 
hydroxyoctadecadienoic acid, nitrotyrosine, and dityrosine in plasma of high-fat fed nondiabetic 
mice [5] compared to mice fed a standard diet. 
 Although the evidence is strong to suggest that dyslipidemia and other lifestyle factors 
influence the development of neuropathy, the mechanisms by which this phenomenon occurs are 
poorly understood. Vincent and colleagues have recently proposed the theory that oxidized low-
density lipoproteins (oxLDLs) are one “lipid factor” responsible for nervous system injury in 
diabetic neuropathy [5, 7]. The oxLDL theory is currently the only proposed mechanism for lipid 
induced neuronal injury and is described below as summarized by Vincent and colleagues [7]. 
LDL is the primary lipoprotein that carries cholesterol in the plasma [42]. Importantly, serum 
oxLDL levels are increased in diabetic patients and are associated with diabetic neuropathy [43, 
44] Moreover, oxLDLs are increased in the DRG of high-fat fed mice that exhibit early signs and 
symptoms of diabetic neuropathy [5].  
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 Oxidative stress can cause modification of lipoproteins and this is well characterized in 
the atherosclerosis literature [43, 44]. When in the presence of reactive oxygen species (ROS) 
such as superoxide, LDLs spontaneously oxidize to form oxLDLs [7, 42]). oxLDLs have been 
shown to cause apoptotic injury and cell death in endothelial cells [45] and neurons [46-48]. 
Furthermore, oxLDLs increase ROS and activate a caspase-3 dependent cell death mechanism 
[49] in motoneurons. 
 oxLDLs primarily bind to two cell surface receptors including lectin-like oxidized LDL 
receptor-1 (LOX-1) on endothelial cells [50] and CD36 on macrophages [51]. After binding to 
its receptor, oxLDL is taken up into the cell [52]. The potential effects of oxLDL binding are 
illustrated in Figure 1 from Vincent et al. [7] Increased oxLDL levels upregulate LOX-1 
expression and consequently cause increased intracellular superoxide production [53]. 
Interestingly, TNF-α [53], hyperglycemia, and C-reactive protein (CRP) increase LOX-1 
expression [54-56], whereas lipid-lowering drugs decrease its expression [57]. Indeed, LOX-1 is 
expressed on neurons, and LOX-1 gene polymorphisms are associated with neurodegenerative 
disease in humans [46]. After exposure to oxLDL, LOX-1 expression was increased in cultured 
DRG neurons from rats [5]. Following oxLDL exposure and LOX-2 activation, NADPH oxidase 
was subsequently activated (a non-mitochondrial source of superoxide) and consequently, 
superoxide generation was increased and a programmed cell death mechanism was activated in 
the DRG neurons. Importantly, neuronal injury in the DRG was prevented by a LOX-1 blocking 
antibody, apocyanin (NADPH oxidase inhibitor), or the antioxidant α-lipoic acid [5].  
 Native LDL receptors on neurons play a critical role in neuron function, synapse 
maintenance, and myelination after injury [58] and oxLDL decreases LDL receptor expression 
[53]. Therefore, increased oxLDL, via reduced native LDL receptor expression, may contribute  
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Figure 1. Putative mechanisms for dyslipidemia-induced sensory neuron injury. 
Schematic diagram illustrating the DRG, with an enlarged inset of a DRG neuron and adjacent 
blood vessel.  The oxidized form of LDL (oxLDL) binds to the LOX-1 receptor in vascular 
endothelial cells and DRG neurons and is subsequently endocytosed or transcytosed. oxLDL is 
thought to activate NADPH oxidase via interactions with the LOX-1 receptor, resulting in non-
mitochondrial superoxide generation. In addition, NADPH oxidase may increase mitochondrial 
production of reactive oxygen species. Finally, glucose may independently induce mitochondrial 
superoxide production and increase endothelial LOX-1 expression. This schematic illustration 
was adapted from Vincent et al. [7] with permission from John Wiley and Sons, Ltd.  
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Figure 1 
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to neuronal injury in individuals with dyslipidemia. These data suggest that dyslipidemia via a 
LOX-1 dependent mechanism increases ROS generation (independent of hyperglycemia) and 
induces neuronal damage [7]. Furthermore, when dyslipidemia occurs in the presence of 
hyperglycemia, neurons may be sensitized to oxLDL-mediated damage due to hyperglycemia-
induced upregulation of LOX-1 [7]. These important findings reveal a plausible mechanism to 
explain the influence of dyslipidemia in the pathophysiology of diabetic neuropathy [5, 7].   
 
Mitochondrial Dysfunction  
 Mitochondrial dysfunction has been suggested to be another important etiological factor 
in the multifactorial pathogenesis of diabetic neuropathy. Mitochondria perform several 
important physiological functions, with energy production being the central and perhaps most 
vital of these functions. Cells rely on energy produced by mitochondria for all cellular processes 
including cell growth and maintenance, protein synthesis, and cellular transport. Neurons, due to 
their relatively high metabolic demands, rely heavily on mitochondrial energy production, which 
is essential for neuronal growth and survival and maintenance of membrane potential [59]. 
Neurons often have long processes that require mitochondria to travel long distances from the 
cell body to the dendritic and axonal termini [60]. Consequently, metabolic disturbances that 
alter normal mitochondrial function are especially detrimental to neurons, particularly those 
innervating the distal limbs which are most often affected in diabetic neuropathy [59]. Because 
neurons are so sensitive to perturbations in mitochondrial function, it is not surprising that 
mitochondrial dysfunction has been implicated in the pathogenesis of many neurological 
disorders [61].      
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 Mitochondria participate in numerous physiological functions including fatty acid 
oxidation, maintenance of calcium homeostasis, cellular apoptosis, oxidative phosphorylation 
and ATP production. Mitochondria produce ATP by passing electrons down the electron 
transport chain that is comprised of a series of oxidative phosphorylation complexes located in 
the mitochondrial inner membrane space. NADH and FADH2 serve as electron donors to the 
mitochondrial membrane electron transport chain (ETC) enzyme complexes. Electrons are 
shuttled through these enzyme complexes until they are donated to molecular oxygen, forming 
water. The electron transfer produces a proton gradient between the inner and outer 
mitochondrial membrane that drives ATP synthesis [62].  Recent reports indicate mitochondrial 
dysfunction occurs in peripheral neurons of diabetic animals and suggest these mitochondrial 
disturbances contribute to development of diabetic neuropathy [63-66]. Studies performed using 
cultured DRG isolated from diabetic animals reported decreased mitochondrial respiration and 
maximal respiratory capacity, reduced mitochondrial enzyme complex activity, and decreased 
expression of mitochondrial oxidative phosphorylation proteins, compared to nondiabetic 
animals [63, 64, 66]. In addition, cultured DRG neurons from diabetic animals exhibit aberrant 
mitochondrial trafficking, mitochondrial accumulation in axon swellings, and altered 
mitochondrial fission-fusion equilibrium resulting in small mitochondria with ultrastructural 
abnormalities [64, 67-70]. Furthermore, changes in mitochondrial number and size have been 
reported in the Schwann cells of myelinated and unmyelinated axons during peripheral nerve 
regeneration in diabetic humans and animals [71]. 
 To date, all published studies of mitochondrial dysfunction in diabetic rodents have been 
performed in primary DRG cultures, raising the question of whether mitochondrial dysfunction 
drives the development of neuropathy or if it is merely a consequence of neuronal damage [64, 
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67-70]. When studied in culture, neurons are in a regenerative state of repair, thus observations 
of mitochondrial dysfunction in cultured DRG neurons may suggest that mitochondrial 
dysfunction plays a role in impaired nerve regeneration that occurs downstream of dying-back 
axonal degeneration in diabetic neuropathy.   
 
The Role of Oxidative Stress in Mitochondrial Dysfunction 
The term oxidative stress refers to the excess production of reactive oxygen species 
(ROS) and reactive nitrogen species (RNS) [18]. As electrons are passed from oxidative 
phosphorylation complex II to III in the electron transport chain, ROS are produced as 
byproducts.  In normal metabolism, ROS production is minimal and antioxidant enzymes 
including superoxide dismutase, catalase, and glutathione function to detoxify the mitochondria 
of ROS [18, 62]. Hyperglycemia causes increased glucose metabolism that generates an 
overabundance of NADH and FADH2 electron donors. This produces a high proton gradient 
across the inner mitochondrial membrane, which increases the turnover of the enzyme 
complexes, and results in increased levels of ROS [18, 62]. Subsequently, ROS production 
exceeds the detoxifying capability of the mitochondrial antioxidant enzymes. Oxidative stress 
can also activate the p-ADP ribose (PARP) pathway [72], which in conjunction with the 
hexosamine and protein kinase C (PKC) pathways, induces inflammation and neuronal 
dysfunction [3]. In addition, oxidative stress in combination with hyperglycemia activates 
advanced glycation end product (AGE), polyol, hexosamine, and PKC pathways which lead to 
further oxidative stress, cellular redox imbalance, and gene expression disturbances [3]. 
Activation of these detrimental pathways can also induce inflammation and neuronal dysfunction 
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[3]. Since excess ROS results in activation of these detrimental pathways that produce additional 
ROS, oxidative stress becomes a cyclical problem.  
 Despite the fact that mitochondria are a source of ROS, they are often the first structures 
to be damaged, thus putting the neuron at greater risk [18]. ROS accumulation can be very 
detrimental to mitochondrial DNA, mitochondrial membranes, and the whole cell [3, 62]. 
Diabetic mice have decreased levels of superoxide dismutase suggesting reduced capacity for 
ROS detoxification [67]. However, decreased mitochondrial respiration was not associated with 
increased ROS production in these studies [66, 67]. Taken together, these data suggest that 
diabetes-induced mitochondrial dysfunction does not necessarily result in increased 
mitochondrial ROS generation [66]. Mitochondrial dysfunction has been identified an important 
etiological factor in the pathogenesis of diabetic neuropathy, but the contributions of 
mitochondrial dysfunction in diabetic neuropathy remain controversial [20, 22, 66, 73]. 
  
Inflammation 
 Inflammatory mechanisms play an important role in the pathogenesis of both type 1 and 
type 2 diabetes and have recently been implicated as key mediators in the progression of diabetic 
complications including nephropathy, retinopathy, and neuropathy [74]. Diabetes is typically 
accompanied by a chronic state of whole body low-grade inflammation that can be exacerbated 
by hyperglycemic fluctuations [75]. Characteristic of chronic inflammation, pro-inflammatory 
cytokines including tumor necrosis factor alpha (TNF-α), C-reactive protein (CRP), interleukin 
(IL)-6, and IL-1β are elevated in serum from diabetic patients [76, 77]. Adipose tissue is a key 
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source of pro-inflammatory cytokines and inflammatory markers are also increased in adipose 
from diabetic humans and rodents [77, 78].  
 Inflammation has been identified as a mechanism contributing to insulin resistance [76], 
thus this line of research has more often focused on the role of inflammation in type 2 diabetes 
rather than type 1 diabetes.  Obesity, a common concomitant condition with type 2 diabetes, can 
also induce inflammation and is associated with chronic low-grade inflammation [79-82]. It is 
also purported that diet-induced hyperlipidemia may contribute to inflammation and diabetic 
complications [40, 83]. Although the role of chronic inflammation in the pathogenesis of type 1 
diabetes is not well understood, increased pro-inflammatory cytokines and chemokines have 
been documented in type 1 diabetic patients [84, 85]. It has been suggested that inflammation 
plays a larger role in the long-term progression of type 1 diabetes rather than its onset [86]. 
Although inflammation may play slightly different roles in the progression of type 1 and type 2 
diabetes, it is clear that the inflammatory process is linked with the development of diabetic 
complications [74, 86]. Hyperglycemia, a feature common to both type 1 and type 2 diabetes, 
acts deleteriously on a number of pathways including the aldose reduction, AGE, reactive 
oxygen intermediate, and protein kinase C pathways [86]. All of these pathways can induce the 
production of inflammatory mediators that, in turn, activate innate immune cells, which can 
damage the pancreas, adipose and vasculature, thus leading to further diabetic complications 
[76]. Although this pro-inflammatory process is essential for tissue damage and repair, chronic 
activation can lead to pathological changes and result in disease [87]. 
 Numerous studies have documented increased inflammatory mediators in serum and 
tissues of humans and rodent models of diabetes and in many cases, these increases were 
specifically linked to diabetic neuropathy (reviewed in [88]). Of the cytokines, many of the 
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interleukins and TNF-α have been implicated in neuropathic conditions. Nondiabetic patients 
with small-fiber neuropathy show increased gene expression of IL-2 in peripheral blood and 
increased Il-6 and IL-8 in skin biopsies compared to control subjects [89]. Importantly, further 
study revealed that these patients had robust increases in IL-1β, Il-6, and Il-8 mRNA in skin 
affected by spontaneous pain compared to unaffected skin [89]. Sural nerve biopsies from 
patients with diabetic neuropathy also reveal increased Il-6 protein expression compared to 
healthy controls [90]. In addition, STZ-induced diabetic mice with neuropathy have increased 
IL-6 gene expression in the DRG and sciatic nerve compared to nondiabetic mice [89, 90].  
 TNF-α is a classic pro-inflammatory cytokine that can induce nociceptive behavior in 
rodents [91] and ectopic firing [92] in sensory neurons, and has been implicated in neuropathic 
and inflammatory nociceptive conditions in numerous studies over several years [88]. Although, 
TNF-α has only recently begun to be studied in diabetic neuropathy, TNF-α has quickly become 
the inflammatory mediator with the strongest evidence linking diabetic neuropathy and 
inflammation [88]. Diabetic patients and STZ-diabetic rodents have increased TNF-α plasma 
protein and mRNA levels compared to nondiabetic controls [93-98]. To substantiate the 
importance of TNF-α in the development of diabetic neuropathy, TNF-α null mutant diabetic 
mice fail to develop the nocifensive behavior changes and sensory and motor nerve conduction 
deficits that are normally observed in diabetic wild-type mice [99]. Furthermore, treatment with 
a TNF-α neutralizing antibody ameliorated diabetic neuropathy in STZ-induced diabetic mice 
[99].  
 Although greater focus has been placed on the role of cytokines in diabetic neuropathy, 
increased levels of other inflammatory mediators including chemokines, NF-κβ, toll-like 
receptors (TLRs) [100], and cyclooxygenase-2 (Cox-2) [101-103] have also been documented in 
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diabetic rodents and/or humans with neuropathy. NF-κβ is a transcription factor that induces 
several inflammatory and immune mediators and increased NF-κβ activation has been reported 
in several tissues in diabetic patients and in the DRG, sural, and sciatic nerve of diabetic mice 
[90, 104, 105]. Activated TLRs induce NF-κβ and subsequently increase cytokine and 
chemokine expression [88]. Type I diabetic patients exhibit increased circulating levels of TLR 
ligands and increased TLR2 and TLR4 monocyte surface expression [100]. Clinical studies 
indicate diabetic patients have increased Regulated on Activation Normally T-cell Expressed and 
Secreted (RANTES) and Monocyte Chemoattractant Protein-1 (MCP-1) levels compared to 
healthy control subjects [106, 107]. Furthermore, diabetic patients with neuropathy had increased 
circulating RANTES levels compared to diabetic patients without neuropathy while increased 
serum MCP-1 was positively correlated with peripheral neuropathy in diabetic patients [106, 
107].  
 It has been suggested that cytokine levels may play a role in dictating whether a patient 
experiences a painful or painless phenotype of neuropathy. In fact, clinical studies have indicated 
that patients (not necessarily diabetic) with painful neuropathy have increased serum TNF-α and 
IL-2 compared to patients with painless neuropathy [95]. In addition, patients with painless 
neuropathy had increased IL-10, an anti-inflammatory cytokine, compared to patients with 
painful neuropathy [95]. In support of the clinical data, STZ-induced diabetic rats with 
hypoalgesia have decreased protein levels of TNF-α in the DRG [108] while STZ-diabetic rats 
that exhibit hyperalgesia display increased TNF-α levels in the DRG [99].  Taken together, these 
data make a strong case for the role of inflammatory mediators in the pathogenesis of diabetic 
neuropathy, with specific emphasis on the painful neuropathy phenotype. 
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Peripheral Nervous System Insulin Resistance 
  Insulin resistance has been well established as a central feature of type 2 diabetes and is 
defined as reduced target tissue responsiveness to normal levels of circulating insulin [109]. 
While insulin deficiency is the primary factor in the pathogenesis of type 1 diabetes, patients 
with type 1 diabetes can also develop insulin resistance [110, 111]. In fact, recent evidence 
suggests insulin resistance contributes to micro- and macro- vascular complications in type 1 
diabetes [110-113]. In type 2 diabetes, insulin resistance is the key feature of this disease and the 
primary cause of hyperglycemia. Insulin resistance in the setting of diabetes has been thoroughly 
characterized in insulin-dependent tissues including muscle, fat, and liver [114-116]. Although 
neurons are not insulin-dependent, they are insulin-responsive, and emerging evidence now 
demonstrates that insulin resistance also occurs in neurons [117, 118]. Importantly, reduced 
neuronal insulin signaling (due to insulin deficiency in type 1 or insulin resistance in type 2 
diabetes), has recently been proposed as a mechanism contributing to neurodegeneration and the 
pathogenesis underlying diabetic neuropathy [117, 119]. 
 Insulin is an essential hormone required for maintaining glucose homeostasis via 
regulation of hepatic gluconeogenesis and glucose uptake by muscle and liver. Insulin is critical 
for glucose uptake in muscle and adipose, but neuronal glucose uptake occurs in an insulin-
independent manner [120]. Although neurons are not dependent on insulin for glucose update, 
neurons rely on insulin as a key neurotrophic factor important for neuronal growth [121, 122],  
plasticity, regeneration [123-125], and maintenance of mitochondrial function [21, 66]. 
 Insulin signaling occurs in a series of phosphorylation events following insulin binding to 
its extracellular receptor [126]. Following insulin binding, the insulin receptor 
autophosphorylates, becomes activated, and subsequently phosphorylates several intracellular 
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substrates including members of the insulin receptor substrate (IRS) family on their tyrosine 
residues [127]. Tyrosine phosphorylation on IRS allows downstream signaling molecules 
containing Src homology 2 domains (SH2) to bind IRS, then localize to the plasma membrane 
thereby becoming activated [128]. Growth factor receptor-binding protein-2 (Grb-2) and PI-3 
kinase are two of the key SH-2 containing mediators that undergo activation by IRS [128, 129]. 
Insulin signals through two different pathways: PI-3 kinase activates the Akt cascade while Grb-
2 activates the mitogen-activated protein kinase (MAPK) branch of insulin signaling [109]. In 
insulin dependent tissues via the Akt cascade, insulin stimulates glucose uptake by inducing 
Glut4 translocation to the plasma membrane, glycogen synthesis, protein synthesis via mTor 
activation, fatty acid synthesis, promotes cell survival, and inhibits lipolysis. In addition, insulin 
signaling stimulates cell growth and mitogenesis through activation of the MAPK cascade [109].  
 A growing body of evidence documenting impaired neuronal insulin signaling in animal 
models of diabetic neuropathy supports the idea that neuronal insulin resistance is an important 
mechanism contributing to the pathogenesis of diabetic neuropathy. Metabolic disturbances 
including obesity, hyperglycemia, hyperinsulinemia, and inflammation can cause disturbances in 
the insulin signaling pathway [109]. In pathological conditions, serine phosphorylation on IRS 
replaces the normal IRS tyrosine phosphorylation thus inhibiting normal insulin signal 
transduction and downstream effects [128-131]. In fact, increased serine phosphorylation on 
IRS2, the prevalent neuronal IRS isoform, has been reported in DRG neurons from type 1 and 
type 2 diabetic mice [132]. Other derangements in the insulin-signaling pathway have been 
reported in the DRG from ob/ob mice including reduced insulin-stimulated Akt activation and 
impaired neurite outgrowth [117, 132]. In addition, low-dose intrathecal, but not subcutaneous, 
insulin injection improved deficits in sensory and motor nerve conduction velocities in type 1 
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diabetic rats without affecting hyperglycemia [119]. Low-dose insulin administration also 
relieved mechanical hyperalgesia in type 1 diabetic rats despite persistent hyperglycemia [133].   
Furthermore, STZ-diabetic rats with moderate insulinopenia without hyperglycemia exhibit 
symptoms of neuropathy [134], suggesting loss of insulin signaling, apart from insulin’s effects 
on glycemia, may be a driving factor behind neuronal damage and degeneration in diabetic 
neuropathy. Taken together, these data suggest that impaired neuronal insulin signaling and 
neurotrophic support, whether due to insulin deficiency or insulin resistance, play an important 
role in the pathophysiology of diabetic neuropathy. 
 
Exercise Intervention as a Preventative and Treatment for Diabetic Neuropathy 
 No definitive cure exists for diabetic neuropathy and current pharmacological 
therapeutics have shown limited success in treating the symptoms of this debilitating disease. 
Antidepressants, antiepileptics, and opioids are commonly used to treat neuropathic pain, yet 
have. limited effectiveness, significant side effects, no impact on hyperglycemia-induced cell 
damage, and no affect on nerve regeneration [135, 136]. Although only a few studies have been 
reported,, exercise has been shown to have both protective [137, 138] and therapeutic effects 
[138, 139] on diabetic neuropathy. Exercise affects the multifactorial pathogenesis underlying 
diabetic neuropathy by targeting numerous pathophysiological mechanisms all at once. In 
addition, exercise can potentially reverse nerve fiber damage, and induce neurogenesis and 
synaptic plasticity [140]. Exercise is safe, effective, and capable of affecting numerous targets 
with limited side effects, and these characteristics are nearly impossible to achieve in single or 
even multiple pharmacotherapeutics.  
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 Numerous reports document the beneficial effects of exercise on mitochondrial 
dysfunction [141-144], oxidative stress [145], dyslipidemia [146, 147] , insulin resistance [148, 
149]  inflammation [150, 151], and neurotrophic support [152]. Aerobic exercise training is well-
known for its ability to improve mitochondrial function and induce mitochondrial biogenesis in 
skeletal muscle and these effects have been frequently studied in both diabetic patients and 
rodents [141-144].  In addition, exercise can increase axonal regeneration through a neurotrophin 
dependent mechanism [152]. Markers of oxidative stress are also diminished after chronic 
exercise training in diabetic patients and diabetic rodents [145, 153]. Additionally, aerobic 
exercise training significantly improves dyslipidemia in nondiabetic and diabetic humans [146, 
154]. Exercise is especially beneficial for improving insulin sensitivity in muscle, liver, and/or 
adipose of diabetic patients and rodents [150, 155, 156]. Furthermore, exercise reduces the level 
of pro-inflammatory cytokines in adipose [150, 153, 157-159], serum [151, 160-164], and liver 
[165]. In fact, recent evidence demonstrates that exercise pre-conditioning prevents brain 
inflammation following stroke suggesting that exercise can modulate inflammation in neural 
tissue [166]. Although this large body of evidence reports exercise-induced improvements in 
several mechanisms that are purported to contribute to diabetic neuropathy in the peripheral 
nervous system, these beneficial effects were observed in other peripheral tissues. Further 
investigation is needed to elucidate the effects of exercise on inflammation, insulin sensitivity, 
oxidative stress, and mitochondrial function in neural tissues, thus shedding light on potential 
mechanisms underlying the beneficial effects of exercise on diabetic neuropathy. 
 Although little research has been done on the effects of exercise on diabetic neuropathy, 
the few studies that have been done indicate exercise can improve and maintain nerve function in 
patients with diabetic neuropathy [137, 139, 167, 168]. In a relatively large longitudinal study, 
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type 1 and type 2 diabetic patients without neuropathy who performed brisk treadmill walking 
for 4 hrs/wk for four years had less incidence of motor and sensory neuropathy than control 
sedentary diabetic patients [137]. In addition, sensory and motor nerve conduction velocities 
were higher in the exercise group and the percentage of diabetic patients who developed 
increased vibration perception threshold was higher in the control group, suggesting exercise 
prevented deleterious sensorimotor changes [137]. Following a 24-week aerobic exercise 
program, sensory and motor nerve conduction velocities were improved in type 2 diabetic 
patients with diabetic neuropathy [139]. Moderate aerobic exercise training has also been shown 
to reduce pain and increase epidermal nerve fiber density [168]. Kluding and colleagues 
executed one of the few human studies that incorporated both aerobic and strength training 
exercise in diabetic patients with neuropathy [169]. After 10 weeks of 3-4 days per week of 
exercise training, diabetic patients with neuropathy had a 30% decline in pain severity, improved 
neuropathy severity score, and increased epidermal nerve fiber branching [169]. These results 
strongly support the use of exercise as a powerful and effective therapeutic for preventing and 
reversing symptoms of diabetic neuropathy in human patients. 
 Exercise studies in rodent models of diabetic neuropathy further corroborate the clinical 
evidence. Treadmill exercise delays the development of thermal and mechanical hyperalgesia in 
STZ-induced diabetic rats compared to sedentary STZ-diabetic rats [170]. In addition, swimming 
exercise prevented motor dysfunction in STZ-induced diabetic rats [138], thus bolstering the 
case for the protective and therapeutic effects of exercise on diabetic neuropathy. Despite the 
lack of understanding surrounding the mechanisms underlying the beneficial effects of exercise 
on diabetic neuropathy, the evidence strongly points to exercise as a promising preventative and 
treatment intervention for this disease.   
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Study Significance 
 Diabetic neuropathy is a debilitating disease that places a significant physical and 
emotional burden on patients who suffer from the unrelenting symptoms. Unfortunately, current 
treatments are inadequate and show limited success at treating the symptoms of this disease.  
Although the majority of diabetic patients will develop some form of peripheral neuropathy, it is 
unknown why some diabetic patients escape neuropathic symptoms. Additionally, it is unclear 
why diabetic neuropathy presents with a dichotomous phenotype such that some patients present 
with painful neuropathy while others experience painless symptoms including loss of sensation. 
 Recently, dyslipidemia has been identified as an independent risk factor for the 
development of neuropathy in diabetic patients [7]. It has also been demonstrated that a high-fat 
diet induces neuropathy in pre-diabetic rodents [5, 23, 41]. When the clinical and basic evidence 
is considered together, it is plausible to suggest that diet plays an important role in the 
development of neuropathy and may have an effect on neuropathy phenotype. The overall goal 
of this body of work is to better understand how lifestyle factors such as diet may predispose a 
diabetic patient to develop neuropathy in an effort to supplement the available pharmaceutical 
treatments with additional clinical guidance. In particular, these studies were aimed at providing 
mechanistic evidence to justify the use of novel therapeutic interventions such as dietary 
modification and exercise to prevent and treat diabetic neuropathy. 
  The goal of the first study (“Phenotypic Changes in Diabetic Neuropathy Induced by 
a High-Fat Diet in Diabetic C57Bl/6 Mice”) was to characterize the effects of a high-fat diet on 
neuropathy development and progression and in nondiabetic and STZ-induced diabetic mice. We 
discovered that a high-fat diet induced mechanical hyperalgesia in both nondiabetic and diabetic 
mice. Considering that STZ-induced diabetic mice normally exhibit insensate neuropathy, the 
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observation that high-fat feeding reverses this phenotype is a transformational finding in the 
diabetic neuropathy field. The three studies that followed were designed to elucidate the potential 
mechanisms underlying high-fat diet-induced mechanical hyperalgesia.  
 In the second study, “Mitochondrial Function in Diabetic Neuropathy”, we examined 
the effects of high-fat feeding on mitochondrial respiration and expression of proteins involved 
in oxidative phosphorylation or mitochondrial function in DRG of nondiabetic and STZ diabetic 
mice. Our findings demonstrated that basal mitochondrial respiration was reduced while 
mitochondrial proteins were elevated in STZ-diabetic mice fed a standard diet. These results 
indicate that diabetes, but not the high-fat diet, induced perturbations in mitochondrial function. 
  In the third study, “The Role of Inflammation in High-Fat Diet-Induced 
Hyperalgesia”, we investigated the effects of high-fat feeding on spinal and peripheral 
inflammation along with microglial activation in nondiabetic and STZ-diabetic mice. Our results 
indicated that high-fat feeding did not increase spinal or peripheral inflammation or induce 
microglial activation in nondiabetic or diabetic mice. 
 In the final study, “The Effects of Exercise on Insulin Signaling in Mice Fed a High-
Fat Diet”, we evaluated the effects of exercise on 1) serum glucose and insulin levels and 2) 
insulin signaling in the DRG, sciatic nerve, and gastrocnemius, in high-fat mice. Diabetic mice 
were not used in this study, as it was designed to determine if exercise could ameliorate high-fat 
feeding-induced impairments in neuronal insulin sensitivity. Our findings demonstrated that 
exercise prevented increased body weight and circulating glucose and insulin levels, normally 
observed in high-fat fed mice. In addition, exercise prevented high-fat diet-induced 
derangements in insulin signaling in the gastrocnemius. The high-fat diet did not result in 
statistically significant impairments in insulin signaling in the DRG or sciatic nerve, nor was 
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insulin signaling in exercised high-fat fed animals were not different from sedentary animals. 
This study reinforced the importance of exercise in preventing or reversing symptoms of diabetes 
and advocates for the use of exercise to prevent or treat complications associated with diabetes.    
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CHAPTER 2 
Phenotypic Changes in Diabetic Neuropathy Induced by a High-Fat Diet in 
Diabetic C57Bl/6 Mice 
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1. Abstract 
Emerging evidence suggests that dyslipidemia is an independent risk factor for diabetic 
neuropathy (reviewed in [7]).  To experimentally determine how dyslipidemia alters diabetic 
neuropathy, we quantified neuropathic symptoms in diabetic mice fed a high-fat diet. 
Streptozocin (STZ)-induced diabetic C57BL/6 mice fed a high-fat diet developed dyslipidemia 
and a painful neuropathy (mechanical hyperalgesia) instead of the insensate neuropathy 
(mechanical insensitivity) that normally develops in this strain. Nondiabetic mice fed a high-fat 
diet also developed dyslipidemia and mechanical hyperalgesia. Thermal sensitivity was 
significantly reduced in diabetic compared to nondiabetic mice, but was not worsened by the 
high-fat diet. Moreover, diabetic mice fed a high-fat diet had significantly slower sensory and 
motor nerve conduction velocities compared to nondiabetic mice. Overall, dyslipidemia resulting 
from a high-fat diet may modify diabetic neuropathy phenotypes and/or increase risk for 
developing diabetic neuropathy. These results provide new insight as to how dyslipidemia may 
alter the development and phenotype of diabetic neuropathy.   
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2. Introduction 
 The prevalence of societal overweight, obesity, and physical inactivity continue to 
increase, thus the influence of lifestyle-related metabolic variables has become increasingly 
important in terms of diabetic neuropathy risk and progression. Data from several large clinical 
trials suggest that dyslipidemia, typically defined as high serum levels of total cholesterol, low-
density lipoprotein cholesterol (LDL-C), high triglycerides, and/or low levels of high-density 
lipoprotein cholesterol (HDL-C) [31], is a major independent risk factor for the development of 
diabetic neuropathy (reviewed in [7]). In addition, dyslipidemia is associated with the onset and 
progression of neuropathy in both type 1 and type 2 diabetes (reviewed in [33]),[34, 35]. Body 
mass index has also been independently associated with the incidence of neuropathy in type 1 
diabetic subjects [38]. Most individuals with neuropathy associated with pre-diabetes have 
painful small-fiber sensory neuropathy, are obese, and have dyslipidemia [11, 171-174]. 
Moreover, results from a cross-sectional study of type 2 diabetic subjects revealed that the 
prevalence of diabetic neuropathy was two-fold higher in type 2 diabetic subjects with the 
metabolic syndrome [175], a condition characterized by dyslipidemia, obesity, and 
hyperglycemia [176].  In support of the clinical evidence, nondiabetic mice fed a high-fat diet 
exhibit dyslipidemia [5], increased body weight, and painful neuropathy characterized by 
mechanical hyperalgesia, thermal hypoalgesia, and nerve conduction deficits [5, 23].  
Although diet was not assessed in the clinical studies, it is plausible to suggest that diet 
may indirectly affect diabetic neuropathy progression and phenotype since dyslipidemia and 
obesity in adult humans can often be attributed to excess energy and fat intake. Taken together, 
this evidence suggests that diet may modulate the progression and phenotype of diabetic 
neuropathy, and these effects may be mediated in part by diet-induced dyslipidemia and/or 
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excess body weight. Although neuropathy and pre-diabetes has been documented in C57Bl/6 
mice fed a high-fat diet [5, 23], the effects of a high-fat diet in conjunction with type 1 diabetes 
has not been studied. Here, we report the effects of a high-fat diet on neuropathy progression and 
phenotype in streptozotocin (STZ)-induced type 1 diabetic mice.   
 
3. Experimental Procedures 
Animals and Diet  
 Seven week-old male C57Bl/6 mice were purchased from Charles River (Wilmington, 
MA), housed two mice per cage under pathogen free conditions, and placed on a 12:12h 
light/dark cycle in the research support facility at the University of Kansas Medical Center. All 
animals had ad libitum access to food and water and were fed a standard diet (8604; Harlan 
Teklad, Madison Wisconsin; 14% kcals from fat, 32% protein, and 54% carbohydrate) or high-
fat diet (07011; Harlan Teklad; 54% kcals from fat comprised of lard and corn oil, 21% protein, 
and 24% carbohydrate). Animals in the high-fat diet group were fed the standard diet for 1 week 
prior to STZ-injection and began the high-fat diet 3 hours post STZ-injection. All protocols and 
procedures were approved by the University of Kansas Medical Center Animal Use and Care 
Committee.  
 
Diabetes Induction  
A single intraperitoneal STZ injection (180 mg/kg body weight; Sigma-Aldrich, St. 
Louis, MO) in 10 mM sodium citrate buffer (pH 4.5) was administered to 8 week-old C57Bl/6 
mice to induce diabetes.  Eight week-old nondiabetic C57Bl/6 mice were injected with 400µl 
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vehicle (sodium citrate) buffer. All mice were fasted for 3 hours pre and post STZ-injection. 
Body weight and blood glucose (glucose diagnostic reagents, Sigma, St. Louis, MO) were 
monitored 1 week post-STZ injection and every week thereafter. Mice with blood glucose levels 
of > 300 mg/dl (> 16 mmol/L) were considered diabetic. STZ-injected mice with blood glucose 
levels below 300 mg/dl were excluded from the study. Treatment groups are abbreviated 
throughout as follows: nondiabetic standard diet (NdStd); nondiabetic high-fat diet (NdHF); 
diabetic standard diet (DbStd); and diabetic high-fat diet (DbHF). 
 
Behavioral Testing 
  Behavioral testing to assess characteristic signs of diabetic neuropathy including 
mechanical sensitivity, thermal sensitivity, and sensorimotor ability (beam walk task) were 
performed 1 week before STZ-injection and subsequently thereafter. Before each behavioral test 
was performed for the first time, mice were acclimated to the apparatus during two separate 
training sessions. Immediately prior to each behavioral test, mice were acclimated to the 
behavior room for 30 minutes followed by a 30-minute acclimation on the testing apparatus 
(except beam walk). 
 Mechanical Sensitivity. Mice were placed on an elevated wire mesh screen (55 cm above 
table), enclosed individually in clear plastic cages (11 x 5 x 3.5 cm), and mechanical sensitivity 
was assessed using a 1.4 g von Frey monofilament (Stoelting, Wood Dale, IL) which was applied 
6 times to each hind paw footpad. A combined mean percent withdrawal from a total of 12 
applications was calculated per mouse and used to calculate group means.  
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 Thermal Sensitivity. Mice were placed on a Hargreaves apparatus and 4.0 V radiant heat 
source was applied four times to each hind paw footpad. Time elapsed before the animal 
withdrew the paw was recorded as withdrawal latency. A combined mean withdrawal latency 
(secs) was calculated from a total of 8 applications per mouse and used to calculate group means. 
 Beam Walk. Mice were trained to traverse a 1 m-long, 1.2 cm diameter, wooden beam 
(adapted from [177, 178]). As each animal crossed the beam, the number of times the right or left 
paw slipped off the beam was counted as a footslip. This behavioral test was recorded using a 
digital video camera. The combined mean number of footslips/mouse was calculated from a total 
of 3 trials per session and used to calculate group means. 
 
Nerve Conduction Velocity 
 At 8 weeks post-STZ and immediately before sacrifice, mice were deeply anesthetized by 
intraperitoneal injection with Avertin (1.25% v/v tribromoethanol [Sigma-Aldrich] c, 2.5% tert-
amyl alcohol [Sigma-Aldrich], dH2O; 200 μL/10 g body weight) and motor and sensory nerve 
conduction velocities were recorded according to Stevens et al. [179] and as described previously 
by Muller et al. [180]. Body temperature was monitored by rectal probe and maintained at 37 0C.  
 
Serum Lipids and Insulin 
 At 8 weeks post-STZ injection and immediately following NCV studies, anesthetized 
mice were sacrificed. Blood was collected into Eppendorf tubes, placed on ice to clot for 30 
minutes, and centrifuged for 15 minutes at 3,000 x g. Serum was removed and frozen at -80oC. 
Serum samples were assayed for total cholesterol (Cholesterol Total E kit, Wako Diagnostics) 
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LDL-C (L-type LDL-C kit, Wako Diagnostics), triglycerides (triglyceride kit, Cayman 
Chemical), and insulin (mouse insulin Elisa, Alpco). 
 
Immunohistochemistry 
Anesthetized mice were sacrificed and tissues were dissected at 8 weeks post-STZ 
injection. Unfixed lumbar dorsal root ganglia (DRG) were dissected and frozen in Tissue-Tek 
O.C.T. Compound (OCT, Sakura, Torrance, CA). Hind paw footpads were dissected and fixed 
for 2 hours in Zamboni’s fixative (4% formaldehyde, 14% saturated picric acid, 0.1 M phosphate 
buffered saline [PBS, pH 7.4] at 4°C), immersed overnight in 1% PBS (pH 7.4 at 4°C), and 
finally immersed for 4 hours in 30% sucrose in 1X PBS (pH 7.4 at 4°C). After freezing in OCT, 
DRG and footpads were sectioned on a cryostat at 10μm and 30μm, respectively, mounted on 
Superfrost Plus slides (Fisher Scientific, Pittsburgh, PA), and stored at. -20°C. 
After thawing for 5 minutes at room temperature, slide mounted tissue was covered with 
blocking solution (0.5% porcine gelatin, 1.5% normal donkey serum, and 0.5% Triton-X in 
Superblock buffer; Pierce) for 1 hour at room temperature. Slides were then incubated overnight 
at 4° C in primary antibody diluted in blocking solution. Slides were washed the following day 
for 2 x 10 min with PBST followed by 3-hour incubation with fluorochrome-conjugated 
secondary antibodies diluted in PBS and blocking solution. Following 2 x 10 min washes in 1X 
PBS, slides were rinsed in deionized distilled H2O, coverslipped and stored at 4 0C (footpad 
sections) or cover slipped with Anti-Fade Prolong Gold (Invitrogen, Carlsbad, CA) and stored at 
room temperature (DRG sections). 
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Intraepidermal Nerve Fiber Density 
 Rabbit anti-PGP 9.5 (1:400; Chemicon, Temecula, CA) and Alexa-488 (1:2000; 
Molecular Probes, Eugene, OR) were used to label and visualize dermal and epidermal nerve 
fibers. Fluorescent digital images were acquired from epidermal regions using a Nikon Eclipse 
E800 microscope. The number of nerve fibers per section that cross the epidermal-dermal border 
were counted using a 40x objective in order to visualize fibers throughout the full depth of the 
tissue section. NIH Image J software was used to measure each epidermal region and 
intraepidermal nerve fiber density (IENFD) was expressed as number of fibers per millimeter of 
epidermis. The combined mean IENFD from 6 images per mouse was used to calculate group 
means.  
 
Oxidative Stress  
 Primary antibodies (rabbit anti-nitrotyrosine [1:1000; Chemicon, Temecula, CA] and 
rabbit anti-neurofilament H [1:10,000, Chemicon, Temecula, CA]) and fluorescent secondary 
antibodies (Alexa 488 and Alexa 555 [both 1:2000; Molecular Probes, Eugene, OR]ere used to 
label and visualize nitrated tyrosine residues and neurons, respectively, in the lumbar DRG. Six 
fluorescent digital images from 6 DRG sections per mouse were acquired at 40x using a Nikon 
Eclipse E80i microscope. All pictures were taken using the identical exposure time. Metamorph 
software (MDS Analytical Technologies, Downington, PA) was used to quantify the mean 
intensity of nitrotyrosine labeling in each image (neuron cell body specific nitrotyrosine 
fluorescence intensity minus background intensity). Compound mean fluorescence intensity from 
6 images per mouse was used to calculate group means. In addition, neuron cell body-specific 
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nitrotyrosine fluorescence intensity was expressed as a percentage of total regions per mouse and 
binned as: low (≤ 300 intensity units), medium (301 – 900 intensity units), or high ( > 900 
intensity units), and used to calculate group means. 
 
Statistics 
  Data were analyzed using a two-factor analysis of variance (ANOVA) or repeated 
measures ANOVA with Fisher’s test of least square difference post-hoc comparisons. Statistical 
significance was set at P < 0.05. 
 
4. Results and Figures 
Body Weight, Glucose, and Insulin 
  Diabetic mice displayed common symptoms of diabetes, including polydipsia and 
polyuria within 1 week after STZ-injection. Typical with this model, diabetic mice weighed less 
than their nondiabetic counterparts. However, high-fat fed diabetic mice gained weight (+3 g) 
compared to diabetics fed the standard diet who lost 1.7 g on average (Figure 1A). Nondiabetic 
mice on the standard diet gradually gained 5 g in body weight, whereas high-fat fed nondiabetic 
mice gained 13 g over the course of the 8-week study (Figure 1A). Energy intake was not 
different among nondiabetic groups (NdStd 13.5 ± 1.3 kcals/day; NdHF 14.0 ± 0.5 kcals/day, P 
> 0.05 for NdStd vs. NdHF). In contrast, diabetic mice on the standard diet consumed at least 2 
times as many kcals/day compared to all other groups (DbStd 29.7 ± 1.8 kcals/day; DbHF 15.2 ± 
7.8 kcals/day, P < 0.05 for DbStd vs. NdStd, NdHF, and DbHF).  
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Figure 1: The effects of STZ-induced diabetes and high-fat feeding on body weight fasting 
blood glucose. 
Both diabetic groups display characteristic signs of diabetes including lower body weight and 
severe hyperglycemia compared to nondiabetic mice. High-fat fed mice gain more weight and 
have lower glucose levels than their standard diet counterparts. Body weight (A) and blood 
glucose (B) (n = 14-21 mice per group). #P  < 0.05 and  ###P < 0.001 for  NdStd vs. NdHF;  +++P 
< 0.001 for NdStd vs. DbStd;  ***P < 0.001 for NdHF vs. DbHF;  ^P < 0.05, ^^P< 0.01, and 
^^^P < 0.001 for DbStd vs. DbHF.  C) Serum insulin (n = 3 – 8 mice per group). *P < 0.05; **P 
< 0.01; ***P < 0.001.  Data are presented as means ± SEM.  
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In nondiabetic mice, high-fat feeding resulted in a mild increase in blood glucose levels 
compared to nondiabetic mice on the standard diet that maintained their blood glucose levels 
around 120 mg/dl throughout the 8-week study (Figure 1B). As early as 1 week following STZ-
injection, diabetic mice had significantly higher blood glucose levels compared to their 
nondiabetic counterparts (Figure 1B). However, the combination of diabetes and the high-fat diet 
resulted in significantly lower blood glucose levels compared to diabetic mice on the standard 
diet, but glucose levels were still higher than both nondiabetic groups (Figure 1B). Insulin levels 
were significantly lower in both diabetic groups compared to the nondiabetic groups on the 
equivalent diet (Figure 1C). Finally, high-fat feeding induced hyperinsulinemia in nondiabetic 
mice (Figure 1C). 
 
A High-Fat Diet Induces Dyslipidemia   
 Nondiabetic mice fed a high-fat diet had higher total cholesterol levels compared to 
nondiabetic mice fed a standard diet (Figure 2A). However, diabetes did not significantly alter 
total cholesterol in mice fed the standard or high-fat diet compared to their nondiabetic 
counterparts (Figure 2A). The high-fat diet increased LDL-C in nondiabetic mice, which 
mirrored the effect of high-fat feeding on total cholesterol in nondiabetic mice (Figure 2A-B). 
Diabetes did not alter LDL-C levels in mice fed the standard diet compared to their nondiabetic 
counterparts (Figure 2B). Triglyceride levels were not significantly affected by the high-fat diet 
in nondiabetic mice (Figure 2C). Diabetic mice on a standard diet had slightly higher 
triglycerides compared to their nondiabetic counterparts, while triglycerides were significantly  
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Figure 2: Serum lipids. 
Blood was collected at 8 wks post-STZ from non-fasted mice. Total Cholesterol (A), LDL-
Cholesterol (B), and Triglycerides (C). Data are presented as means ± SEM (n = 3 – 8 mice per 
group). **P < 0.01 and ***P < 0.001.   
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higher in the diabetic high-fat fed group compared to the nondiabetic high-fat fed group (Figure 
2C). 
 
Sensorimotor Behavior is Altered by High-Fat Feeding 
  Our previous studies of this murine strain have consistently demonstrated that STZ-
induced diabetic C57Bl/6 mice develop a slowly progressive insensate neuropathy characterized 
by a reduction in mechanical sensitivity that appears after 4 weeks of diabetes. However, the 
degree to which individual cohorts of mice develop a loss of sensation has been variable, ranging 
from 27-50% change in sensitivity, and we have never observed mechanical hyperalgesia with 
this model, and mouse strain, and diet. [181-184]. In the current cohort of mice, mechanical 
sensitivity was reduced by 11% (Figure 3A), however, the pattern of mechanical sensitivity 
remained similar to previous studies. In striking contrast, the high-fat diet increased mechanical 
sensitivity in both nondiabetic and diabetic mice compared to their counterparts fed a standard 
diet by 35% and 45%, respectively (Figure 3A). Diabetes significantly reduced thermal 
sensitivity in mice on the standard diet but was not significantly worsened by the addition of the 
high-fat diet (Figure 3B). However, diabetic mice fed the high-fat diet did have significantly 
lower thermal sensitivity than high-fat fed nondiabetic mice (Figure 3B). A beam walk task was 
used to assess sensorimotor ability at 8 weeks post-STZ. The number of hind paw slips measured 
while mice traversed a wooden beam was used to assess sensorimotor deficits and the number of 
slips was not significantly different among any groups (Figure 3C).  
 
 
 
 
 
42 
 
Figure 3: Sensorimotor Behavior.  
A) Mechanical sensitivity was assessed at 8 weeks post-STZ using 12 repeated applications of a 
1.4 g von Frey monofilament (n = 15 – 21 mice per group). B) Thermal sensitivity. Mice were 
placed on a Hargreaves apparatus and a 4.0 V radiant heat source was applied to the hind paw 
footpad. The time elapsed before the animal withdrew the paw was recorded as withdrawal 
latency (n = 6 – 13 mice per group). C) Sensorimotor ability was assessed by quantifying mean 
hind paw footslips as mice traversed a narrow wooden beam (n = 6 - 13mice/group). Data 
presented as means ± SEM. *P < 0.05 and **P< 0.01.  
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Nerve Conduction and Epidermal Innervation 
  Neither diabetes nor high-fat feeding alone altered sensory nerve conduction velocity 
(Figure 4A). Conversely, the combination of diabetes and high-fat feeding significantly reduced 
sensory and motor nerve conduction velocities compared to nondiabetic mice fed the high-fat 
diet (Figure 4A-B). High-fat feeding increased motor nerve conduction velocity (MNCV) in  
nondiabetic mice but MNCV was not significantly affected by diabetes alone (Figure B). 
Consistent with previous studies documenting decreased cutaneous innervation associated with 
diabetic neuropathy [181-183, 185-189], IENFD was significantly reduced in the hind paw 
footpad skin after 8 weeks of diabetes (Figure 5A-C). However, the combination of the high-fat 
diet and diabetes did not significantly alter IENFD (Figure 5C). 
 
Oxidative Stress 
  Immunohistochemistry was used to quantify the abundance of nitrotyrosine, a marker of 
oxidative stress, in the lumbar DRG. Neither diabetes nor the high-fat diet significantly altered 
levels of nitrated tyrosine residues in DRG neuronal cell bodies (Figure 6A-B).  
 
5. Discussion  
Recent evidence indicating that dyslipidemia may increase a diabetic patient’s risk of 
developing neuropathy (reviewed in [7]), taken in conjunction with high-fat feeding studies in 
rodents [5, 23, 190], suggests diet may play an important role in modulating diabetic neuropathy 
progression and phenotype. Here, our data reveals that a high-fat diet fed to STZ-induced  
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Figure 4: Diabetic mice fed a high-fat diet exhibit deficits in nerve conduction velocity. 
Sensory Nerve Conduction Velocity (A) and Motor Nerve Conduction Velocity (B) were 
measured at 8 wks post-STZ. Data are presented as means ± SEM (n = 3 – 8 mice per group). *P 
< 0.05 and ***P < 0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
46 
 
Figure 4 
 
 
 
47 
 
Figure 5: Intraepidermal nerve fiber density is reduced in diabetic mice fed a standard 
diet.  
Plantar skin of the hindpaw was dissected at 8 wks post-STZ. Immunohistochemistry for PGP 
9.5 was used to visualize and count nerve fibers that cross the epidermal/dermal border.  A-B: 
Representative images showing a section of plantar skin used to quantify IENFD. A) 
Nondiabetic Standard Diet. B) Diabetic Standard Diet. Arrows indicate individual axons within 
the epidermis. Scale bar = 50 µM.  C) Quantification of IENFD (n = 11-12 mice per group). Data 
presented as means ± SEM. *P < 0.05 
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Figure 6: Nitrotyrosine expression is increased in lumbar DRG neurons of diabetic mice 
fed a standard diet.  
Quantification of average nitrotyrosine fluorescence intensity per neuron in the lumber DRG. 
Mean fluorescence intensity was calculated for a total of approximately 10 cells per image from 
six images per mouse and group means were calculated with respect cell size. Group means for 
average nitrotyrosine fluorescence per cell are binned by neuron size according to area2: A) 0 – 
200 µm2, B) 201 – 400 µm2, C) 401 – 600 µm2, and D) ≥ 601 µm2. Data are presented as means 
±  SEM (n = 3 – 8 mice per group). *P < 0.05 and **P< 0.01.  
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Figure 7: Representative images showing nitrotyrosine expression in the lumbar DRG.  
A) Nondiabetic Standard Diet, B) Nondiabetic High-Fat Diet, C) Diabetic Standard Diet, and D) 
Diabetic High-Fat Diet. Arrows indicate medium-sized neurons expressing high levels of 
nitrotyrosine. Scale bar = 50 µM. 
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diabetic C57BL/6 mice significantly alters the phenotype of neural symptoms by inducing a 
painful neuropathy (mechanical hyperalgesia) instead of an insensate neuropathy (mechanical 
insensitivity) that normally develops in these diabetic mice [181-184]. In addition, our results 
support clinical data (reviewed in [7]), that suggests that dyslipidemia may be an independent 
risk factor for development of diabetic neuropathy. 
In numerous studies using this murine strain, STZ dose, and standard diet, our laboratory 
has reported that STZ-induced diabetic C57Bl/6 mice develop a slowly progressive insensate  
neuropathy characterized by a reduction in mechanical sensitivity after 4 weeks of diabetes [181-
184, 189]. In the current study, we observed a slight reduction in mechanical sensitivity, 
although the reduction in mechanical sensitivity did not reach statistical significance after 8 
weeks of diabetes in this cohort of animals. Importantly, however, STZ-diabetic mice fed a high-
fat diet displayed a mechanical hyperalgesia, as opposed to the insensate phenotype typically 
observed in this inbred mouse strain. The high-fat diet induced a robust mechanical hyperalgesia 
as mechanical sensitivity was increased by 35% and 45%, respectively, in nondiabetic and 
diabetic mice compared to their counterparts fed a standard diet. This finding is particularly 
important because it suggests that diet modulates diabetic neuropathy phenotype in rodents, thus 
dietary manipulation could be used as a new tool to investigate mechanisms that cause some 
patients to experience insensate symptoms while others have painful symptoms. In addition, this 
data is consistent with previous studies that reported that a high-fat diet induces neuropathy in 
nondiabetic mice [5, 23]. 
Diet-induced changes in neuropathy were not uniform across modalities or symptoms.  
For example, diabetes significantly reduced epidermal innervation as previously noted [181-
183]; however, the high-fat diet alone or in combination with diabetes did not further affect 
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IENFD. Similarly, impaired thermal sensitivity was not exacerbated by the high-fat diet in STZ-
diabetic mice. This suggests that diabetes alone may be the driving factor underlying reduced 
IENFD and thermal hypoalgesia in this model. 
Neither diabetes nor the high-fat diet significantly altered gait and balance as assessed by 
the beam walk task. Body weight differences due to the high-fat diet appeared to affect the beam 
walk task that potentially confounded this data, increased error, and reduced our ability to detect 
statistically significant differences in hind paw footslips. In addition, gait and balance deficits 
detected by a beam walk task are thought to be, in part, attributed to altered muscle spindle group 
Ia innervation [180], which may not be affected after only 8 weeks of diabetes. 
  Behavioral responses to sensorimotor tests incorporate inputs from multiple axonal fiber 
types within peripheral nerves. The von Frey method of assessing mechanical sensitivity 
stimulates a combination of large myelinated A-beta fibers that are sensitive to light touch and 
small unmyelinated C fibers that are pain-responsive. The Hargreaves test stimulates pain and 
temperature-sensing C and A-delta fibers, whereas the beam walk test likely assesses 
contributions from dermal A-fibers and muscle afferent fibers innervating muscle spindles, both 
of which are important for gait, balance, and proprioception. IENFD is an excellent tool for 
quantifying small fiber loss, is often used when diagnosing diabetic neuropathy in humans, and 
has been shown to correlate with diabetes duration in human patients [17, 180, 185, 191]. 
Slowed SNCV has been thought to reflect conduction deficits predominately in large fibers 
[180], but reports documenting diabetes-induced slowed SNCV vary as some studies report 
decreases [192] while others report no change [180, 193]. The diabetic environment affects each 
fiber population differently and the type of fibers predominantly affected varies with mouse 
strain and in humans. 
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 In the current study, the high-fat diet induced mechanical hyperalgesia, but diabetes-
induced deficits in thermal sensitivity were only mildly worsened by the addition of the high-fat 
diet. Neither diabetes nor the high-fat diet significantly altered gait and balance as assessed by 
the beam walk task. Apart from the robust effects of the high-fat diet on mechanical sensitivity, 
none of the other behavioral data nor anatomical or physiological assessments performed here 
suggest that the high-fat diet affects sensorimotor behavior or nerve morphology and function 
differently than diabetes alone. It will be important to investigate how a high-fat diet alters 
mechanical sensitivity, and whether this selective effect is related to specific peripheral fiber-
type or central processing of mechanical sensitivity in the CNS. 
 Here, we report that a high-fat diet significantly increased body weight in nondiabetic and 
diabetic mice compared to their counterparts on a standard diet, suggesting that the metabolic 
derangements that accompany diet-induced obesity may have harmful effects on nerve fiber 
function, thereby leading to mechanical hyperalgesia. 
 In addition, total cholesterol and LDL-C were significantly increased in high-fat fed 
nondiabetic mice compared to their nondiabetic counterparts on the standard diet and triglyceride 
levels were significantly higher in STZ-diabetic mice fed the high-fat diet compared to their 
nondiabetic counterparts on the high-fat diet. Because at least one parameter of the lipid profile 
(serum total cholesterol, LDL-C, or triglycerides) was increased in high-fat fed nondiabetic and 
STZ-diabetic mice, both groups could be considered dyslipidemic. Thus, diet-induced 
dyslipidemia may be an underlying factor that drives mechanical hyperalgesia in rodents. 
Consistent with clinical evidence suggesting dyslipidemia is associated with diabetic neuropathy 
onset and progression (reviewed in [33]),[34, 35], our data supports the view that diet-induced 
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dyslipidemia may induce neuropathy in pre-diabetic patients and modulate diabetic neuropathy 
onset, progression, and/or phenotype. 
 In the current study, nondiabetic mice fed the high-fat diet exhibited pre-diabetes 
characterized by elevated glucose levels and hyperinsulinemia. As expected, glucose was 
significantly higher in both diabetic groups compared to their nondiabetic counterparts. 
However, glucose levels were lower in high-fat fed diabetics compared to diabetic mice on the 
standard diet which is most likely explained by the lower percentage of total kilocalories derived 
from carbohydrate in the high-fat diet (24%) versus the standard diet (40%). STZ is a selective a 
beta islet cell toxin that kills the insulin producing cells in the pancreas, thus, as expected, insulin 
levels were significantly lower in both diabetic groups compared to their nondiabetic 
counterparts. Although high-fat feeding induced mechanical hyperalgesia in both nondiabetic 
and diabetic mice, nondiabetic mice were hyperinsulinemic whereas diabetic mice remained 
hypoinsulinemic after 8 weeks of high-fat feeding. Furthermore, diabetic mice on the high-fat 
diet had significantly higher glucose levels than their nondiabetic counterparts but mechanical 
sensitivity was not different between these groups. Thus, our data suggests that glucose and 
insulin levels may not be key factors driving high-fat diet induced mechanical hyperalgesia 
observed in the current study.  
 A high-fat diet and diabetes alone have consistently been shown to increase oxidative 
stress in rodents [5, 72, 190, 194, 195] and increased oxidative stress has been proposed as a 
mechanism that contributes to pathogenesis of diabetic neuropathy (reviewed in [18, 196, 197]). 
Vincent and colleagues reported that dyslipidemia leads to high levels of oxidized low-density 
lipoproteins (ox-LDLs) in mice and in vitro and oxLDLs lead to severe DRG neuron oxidative 
stress and neuron injury, thus identifying a potential mechanism by which dyslipidemia may 
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contribute to the development of diabetic neuropathy [5]. However, nitrotyrosine levels in the 
DRG were not altered by diabetes or the high-fat diet in the current study. These results should 
be interpreted with caution because we only quantified one oxidative stress marker in one tissue 
(DRG), and this was a short-term study that lasted only 8 weeks. Although nitrotyrosine levels 
were not affected in the DRG, it is possible that diabetes and/or the high-fat diet increased 
oxidative stress and these effects may have been more apparent if we had quantified additional 
oxidative stress markers (i.e. hydroxyoctadecadienoic acid, 4-hydroxynonenal, dityrosine) in the 
DRG or other tissues such as plasma, isolated LDLs, or sciatic nerve.  
 Little is known about the mechanisms contributing to high-fat diet-induced painful 
neuropathy, but one recent study indicates that an extract from the Artemisia plant (known for its 
anti-inflammatory and anti-nociceptive properties) alleviates high-fat diet induced mechanical 
hyperalgesia and reduces 12/15 lipoxygenase (regulates pro-inflammatory cytokine production) 
upregulation, suggesting that inflammation may play a role in high-fat diet induced neuropathy 
[190]. Pro-inflammatory cytokines and chemokines have been widely implicated in chronic pain 
and are thought to contribute to the central sensitization that results in mechanical hyperalgesia 
[198-201]. Importantly, obesity is associated with chronic low-grade inflammation [79, 80], and 
a high-fat diet increases the pro-inflammatory cytokines IL1-β, tumor necrosis factor alpha 
(TNF-α), C-reactive protein (CRP), and IL1-6, and stimulates inflammatory signaling in adipose, 
serum, liver, and brain [124, 202-205]. Along with glia and macrophages [206-211], adipose is 
an important source of pro-inflammatory cytokines that may upregulate cytokine production due 
to increased adipose resulting from a high-fat diet [124, 202]. Therefore, a pro-inflammatory 
environment in the spinal cord may be a key mechanism in the development of mechanical 
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hyperalgesia associated with diabetes and/or a high-fat diet. Future studies will investigate the 
role of spinal inflammation in high-fat diet induced mechanical hyperalgesia.  
  
Conclusions 
  These results demonstrate that a high-fat diet fed to STZ-induced diabetic C57BL/6 mice 
significantly alters the phenotype of neural symptoms by inducing a painful neuropathy 
(mechanical hyperalgesia) instead of the insensate neuropathy (mechanical insensitivity). In 
addition, our results support previous studies [5, 23] that show a high-fat diet fed to nondiabetic 
mice can induce pre-diabetes and neuropathy. In conclusion, dyslipidemia resulting from a high-
fat diet, may modify diabetic neuropathy phenotype and/or increase risk for developing diabetic 
neuropathy. Furthermore, the metabolic defects that accompany diet-induced obesity may have 
harmful effects on nerve fiber function thereby leading to mechanical hyperalgesia. These results 
may provide some insight into why some patients develop painful versus insensate neuropathy.  
 Although the ability of a high-fat diet to induce mechanical hyperalgesia is novel, little is 
known about the mechanisms responsible for this robust painful diabetic neuropathy phenotype 
in this model, thus further study is warranted.  Positive outcomes from future studies could lead 
to dietary modifications and/or increased use of treatments that improve dyslipidemia (i.e. omega 
3 fatty acid supplementation, statins, or exercise) as therapeutic interventions for patients with 
painful diabetic neuropathy. 
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CHAPTER 3 
Mitochondrial Function In Diabetic Neuropathy 
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1. Abstract  
 Mitochondrial dysfunction has been proposed as a contributory mechanism driving 
diabetic neuropathy. In contrast, several recent studies suggest that mitochondrial dysfunction is 
subtle and occurs in late stages of diabetes. Experiments here used a high-fat diet to exacerbate 
the severity of diabetes and to expedite the time-course in which mitochondrial dysfunction 
occurs. We hypothesized that a high-fat diet in addition to diabetes would create added stress to 
sensory neurons and exacerbate mitochondrial dysfunction. Mitochondrial respiration 
measurements and expression of proteins involved in oxidative phosphorylation or mitochondrial 
function were quantified in the dorsal root ganglia. Comparisons were made between nondiabetic 
and STZ-induced diabetic C57Bl/6 mice consuming a standard or high-fat diet for 8 weeks. 
Basal mitochondrial respiration was significantly reduced in diabetic mice fed a standard diet 
compared to their nondiabetic counterparts. There were no differences among groups in leak 
dependent respiration, maximal respiration, spare respiratory capacity, or expression of subunits 
from oxidative phosphorylation complexes I, II, or V. In contrast, Complex III subunit Core-2 
and voltage dependent anion channel (VDAC) were significantly increased in diabetic mice 
compared to nondiabetic mice fed the standard diet (p< 0.05). There were also no differences 
among groups in UCP2, PGC-1α, PGC-1β levels or Akt, mTor, or AmpK activation. These data 
suggest subtle mitochondrial dysfunction and potential compensatory mitochondrial biogenesis 
occurs after 8 weeks of STZ-induced diabetes and these parameters are not altered by high-fat 
feeding. Our results support the idea that mild mitochondrial dysfunction occurs early in the 
diabetic progression suggesting that mitochondrial impairment may play a role in the dying-back 
type axonal degeneration that occurs in diabetic neuropathy. 
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2. Introduction  
Neurons, due to their relatively high metabolic demands, rely heavily on mitochondrial 
energy production, which is required for many cellular processes including protein synthesis, 
growth and survival, and neuronal excitability [59]. Consequently, metabolic disturbances that 
alter normal mitochondrial function are especially detrimental to neurons [59]. Thus, it is not 
surprising that mitochondrial dysfunction has been implicated in the pathogenesis of many 
neurological disorders [61].  
Mitochondrial dysfunction has been identified an important etiological factor in the 
pathogenesis of diabetic neuropathy, but the contributions of mitochondrial dysfunction in 
diabetic neuropathy remain controversial [20, 22, 63, 64, 66, 73]. Diabetes has been shown to 
attenuate mitochondrial respiration and spare respiratory capacity, reduce activities of 
mitochondrial enzyme complexes I and IV, and decrease expression of mitochondrial oxidative 
phosphorylation proteins in cultured DRG isolated from diabetic animals compared to 
nondiabetics [63, 64, 66]. In addition, cultured DRG neurons from diabetic animals exhibit 
mitochondrial accumulation in axon swellings and altered mitochondrial fission-fusion 
equilibrium resulting in small mitochondria with ultrastructural abnormalities [67-70]. 
Furthermore, a distal dying-back axonal degeneration is predominant in Charcot-Marie-Tooth 
disease type 2 (CMT2) and mutations in the mitochondrial fusion protein, mitofusin 2, are the 
most common cause of CMT2 that has been identified to date [212]. Together, these results 
suggest that mitochondrial damage and dysfunction may play a role in the distal dying-back 
neurodegeneration that occurs in diabetic neuropathy. However, although diabetes has been 
shown to alter mitochondrial function, evidence that mitochondrial dysfunction occurs in 
diabetic models that exhibit significant characteristics of neuropathy is lacking [20, 22, 66, 73].  
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Studies discussed above demonstrated diabetes-induced mitochondrial dysfunction, but in 
all but one study [64], observations were made in models of diabetic neuropathy that lacked 
significant sensory-related behavioral changes and did not show reduced epidermal innervation, 
or neuropathy was not characterized [20, 22, 66, 68, 73]. Thus, further investigation using 
models of diabetic neuropathy that exhibit significant indices of neuropathy are needed to further 
elucidate the role of diabetes-induced mitochondrial dysfunction in diabetic neuropathy. 
Because the prevalence of overweight, obesity, and physical inactivity continue to 
increase in our society, the influence of lifestyle-related metabolic variables (i.e. diet and the 
lipid profile) have become increasingly important in terms of diabetic neuropathy risk in human 
patients. According to the National Health and Nutrition Examination Survey  (NHANES) 1999-
2002, 85.2% of individuals with diagnosed diabetes were overweight or obese [213]. As the 
prevalence of diabetes has risen significantly over the last decade, it is likely the prevalence of 
overweight and obesity in diabetic patients has also increased [1]. Although obesity is a 
concomitant condition in the majority of diabetic patients, rodent studies of diabetic neuropathy 
have typically been conducted in lean animals fed a standard, low-fat diet (≤ 14% kcals from 
fat).  
 To more closely emulate human condition, we used a high-fat diet in conjunction with 
diabetes to examine the effect of diet on neuropathy progression and phenotype. Our previous 
data reveals that a high-fat diet fed to STZ-induced diabetic C57BL/6 mice altered the phenotype 
of neural symptoms by inducing a mechanical hyperalgesia instead of the mechanical 
insensitivity that normally develops in this model of diabetic neuropathy [30]. Interestingly, 
high-fat fed nondiabetic mice also developed mechanical hyperalgesia. Previous rodent studies 
suggest changes in mitochondrial respiration and gene expression are relatively slow, subtle, and 
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do not occur until later stages of diabetes, suggesting hyperglycemia alone may not be driving 
mitochondrial changes in the DRG [64]. Thus, it is important to characterize mitochondrial 
function in this clinically relevant model with a robust behavioral phenotype. Here, we examine 
mitochondrial dysfunction in the DRG as a potential mechanism underlying high-fat diet induced 
neuropathy in nondiabetic and STZ-induced type 1 diabetic mice. 
 
3. Experimental Procedures 
Animals and Diet 
  In this study, animal age, housing conditions, and diets were the same as described in 
Chapter 2. Seven week-old male C57Bl/6 mice were purchased from Charles River (Wilmington, 
MA), housed two mice per cage under pathogen free conditions, and placed on a 12:12h 
light/dark cycle.. All animals had ad libitum access to food and water and were fed a standard 
diet or high-fat diet. Animals in the high-fat diet group were fed the standard diet for 1 week 
prior to STZ-injection and began the high-fat diet 3 hours post STZ-injection. All protocols and 
procedures were approved by the University of Kansas Medical Center Animal Use and Care 
Committee.  
 
Diabetes Induction and Glucose Measurement 
 The diabetes induction, body weight, and glucose measurement protocols used in these 
experiments were identical to the protocol described in Ch. 2. A single intraperitoneal STZ 
injection (180 mg/kg body weight) in sodium citrate buffer was administered to 8 week-old 
C57Bl/6 mice to induce diabetes.  Eight week-old nondiabetic C57Bl/6 mice were injected with  
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vehicle (sodium citrate) buffer. All mice were fasted for 3 hours pre and post STZ-injection. 
Body weight and blood glucose were monitored beginning 1 week post-STZ injection and every 
week thereafter. Mice with blood glucose levels of > 300 mg/dl (> 16 mmol/L) were considered 
diabetic. STZ-injected mice with blood glucose levels below 300 mg/dl were excluded from the 
study. Treatment groups are abbreviated throughout as follows: nondiabetic standard diet 
(NdStd); nondiabetic high-fat diet (NdHF); diabetic standard diet (DbStd); and diabetic high-fat 
diet (DbHF). 
 
Mitochondrial Respiration Measurement 
 Mitochondrial respiration was calculated by systematic inhibition and activation of 
specific components of the electron transport chain (ETC) and oxidative phosphorylation 
machinery using a dual-chambered respirometer (Oro Boros Oxygraph 2K, Innsbruck, Austria). 
At 8 weeks post-STZ or vehicle injection, mice were anesthetized with isofluorane, decapitated, 
and l2 lumbar DRG and peripheral axonal processes were dissected.  Immediately following 
dissection, tissue from each individual mouse was incubated separately at 370 C in 2 ml of 
Dulbecco’s modified eagle culture medium (DMEM # 11966, Gibco-Invitrogen, Carlsbad, CA), 
containing 2.5 mM glucose, 1 mM pyruvate, and 1mM GlutaMAX (Gibco) in the O2 chamber. 
Basal respiration rate was measured after VO2 flux (O2 consumption rate, pmols•sec-1•ml-1) 
stabilized following tissue addition. Next, ATP synthase was inhibited by injection of 3 µl of 
oligomycin (100 mM, Sigma Aldrich)  into the O2 chamber via Hamilton syringe and the 
resultant VO2 flux was used to calculate leak dependent mitochondrial respiration. After O2 flux 
stabilized following oligomycin injection, 2 µl FCCP (3 mM, trifluorobarbonylcyanide 
phenylhydrazone, Sigma Aldrich), was injected into the O2 chamber. FCCP permeabilizes the 
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inner mitochondrial membrane to protons, ameliorates the proton gradient and subsequently 
uncouples electron transport and oxidative phosphorylation, thus allowing the maximal 
mitochondrial respiration rate to be calculated. Finally, 4 µl of antimycin (5 mM, Sigma Aldrich) 
was injected to inhibit complex III of the ETC, thus inhibiting mitochondrial respiration. The 
resultant rate equals non-mitochondrial respiration. Basal respiration, leak dependent respiration, 
and spare respiratory capacity were calculated after subtracting the non-mitochondrial respiration 
rate (O2 flux). Spare respiratory capacity was calculated by subtracting the basal O2 flux rate 
from the maximal O2 flux rate. Immediately following respiration experiments, tissue and culture 
media were removed from the chamber, centrifuged briefly to pellet, media was aspirated, and 
tissue was snap frozen in liquid nitrogen and stored at -800 C until prepared for protein 
extraction.  
Tissues were lysed by sonication in Cell Extraction Buffer (Invitrogen) containing 55.55 
μl/ml protease inhibitor cocktail, 200mM Na3VO4, and 200mM NaF. Following sonication, 
protein was extracted while tissue lysates were kept on ice for 1 hour and vortexed every 10 
minutes. Samples were then centrifuged at 10,000 g for 10 minutes at 40 C and the protein 
concentration of the supernatant was measured using the Bio-Rad protein assay based on the 
Bradford method (Bio-Rad, Hercules, CA). Total protein concentration and VDAC band 
intensity (VDAC/actin arbitrary units, from Western blot) were used to normalize mitochondrial 
respiration data (pmols O2 * sec-1 * mg protein-1 * VDAC -1 ). 
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Western Blots 
 Samples were boiled at 95-100 0C with Lane Marker Reducing Sample Buffer (Thermo 
Scientific, Waltham, MA) for 3 minutes. Samples containing 25µg of protein were separated by 
electrophoresis (35 mA/gel, 0.75 hr, 40 C) on 4-15% gradient tris-glycine polyacrylamide gels 
(Bio-Rad) and transferred onto nitrocellulose membrane (400 mA, 1.5 hr, 40C).  Nitrocellulose 
membranes were blocked for 1 hour at room temperature in blocking solution (5% non-fat 
powdered milk and 0.05% Tween-20 in 0.1 M phosphate buffered saline [PBS, pH 7.4]) 
followed by overnight incubation (40C) in primary antibody diluted in blocking solution (1% 
non-fat powdered milk and 0.05% 0.1 M PBS [pH 7.4]). The following primary antibodies were 
used to probe membranes: Total Ox Phos Antibody Cocktail MS601 (1:200, Mito Sciences, 
Eugene Oregon), total Akt (1:1,000, Cell Signaling), phospho (Ser473) Akt (1:500, Cell 
Signaling), total mTor (1:500, Cell Signaling), phospho-mTor (1:500, Cell Signaling), total 
AmpK (1: 1,000, Cell Signaling), phospho-AmpK (1:1,000, Cell Signaling), PGC-1α (1:500, 
Calbiochem), PGC-1β (1:1000, Abcam)  Sirt1 (1:400, Abcam), VDAC (1:1,000, Calbiochem), 
UCP2 (1:500, Abcam) and actin (1:10,000, Millipore).   
After incubation in primary antibody, nitrocellulose membranes were then washed in 
PBST (0.05% Tween-20 in 0.1 M phosphate buffered saline [pH 7.4]) and incubated for 1 hour 
at room temperature in anti-mouse or anti-rabbit IgG-HRP secondary antibody (Santa Cruz, 
Santa Cruz, CA) diluted 1:5,000 in blocking solution. Bands were visualized by enhanced 
chemiluminescence (ECL) using Supersignal West (Femto or Pico) Substrate (Pierce, Rockford, 
IL) and detected on X-ray film. Bands were quantified via densitometry using NIH Image J 
software.  
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In order to normalize band intensity to total protein or determine phospho/total ratio for a 
specific protein, nitrocellulose membranes were stripped using Restore Plus Western Blot 
Stripping Buffer (Pierce, Rockford, IL), and probed with actin primary antibody (Millipore, 
Billerica, MA) or the total primary antibody corresponding to each phospho-antibody. Bands 
were visualized and quantified as described above.   
 
β-hydroxybutyrate Levels  
 Serum β-hydroxybutyrate levels were quantified to assess ketosis levels. Blood was 
collected into Eppendorf tubes, placed on ice to clot for 30 minutes, and centrifuged for 15 
minutes at 3,000 x g.  Serum was removed and stored at -80oC until assayed with β-
hydroxybutyrate kit (Pointe Scientific) according to manufacturer’s directions. 
 
β-Hydroxybutyrate Treated Cells 
SH-SY5Y neuronal cells were cultured in DMEM high glucose (Gibco #11965) 
supplemented with 10% FBS and 1% penicillin/streptomycin. For experimental procedures, cells 
were plated in 60mm tissue culture dishes and grown to ~90% confluency, then rinsed with 
warm PBS, and treated with DMEM in 5mM glucose supplemented with 10% FBS and 1% 
penicillin/streptomycin +/- 5mM β-hydroxybutyrate (Sigma-Aldrich). After 8 hour in treatment 
medium, cells were rinsed with ice-cold PBS and cell lysates generated using mammalian protein 
extraction reagent (Thermo Pierce #78503) per manufacturer’s instructions. After quantification 
of total protein using DC assay (Bio-Rad #500-0112), samples were denatured in Lane Marker 
Reducing Sample Buffer (Thermo Scientific, Waltham, MA) and subjected to SDS-PAGE 
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electrophoresis and transferred to nitrocellulose membrane as described above. Twenty µg of 
protein was loaded per sample lane. Nitrocellulose membranes were probed separately with 
Total Ox Phos, VDAC, and actin primary antibodies overnight at 40C according to Western blot 
procedures as described above.     
   
Statistics  
 Data were analyzed using a two-factor analysis of variance (ANOVA) with Fisher’s test 
of least square difference post-hoc comparisons. Pearson correlations using two-tailed P-values 
were performed to assess the relationship between β-HB levels and paw percent withdrawal and 
withdrawal latency. Statistical significance was set at P < 0.05.  
 
4. Results and Figures  
Body Weight, Glucose, and Insulin  
 These metabolic data were reported in Chapter 2 and are briefly summarized here. 
Typical with this model of type 1 rodent model of diabetes, diabetic mice weighed less than their 
nondiabetic counterparts. High-fat fed diabetic mice gained weight compared to diabetics fed the 
standard diet who lost weight over the course of 8 weeks. Nondiabetic mice fed the high-fat diet 
were, on average, 10 g heavier than nondiabetic mice fed the standard diet at week 8 of the 
study. Diabetic mice fed the standard diet consumed at least 2 times as many kcals/day compared 
to all other groups. Interestingly, daily energy intake was not increased in nondiabetic or diabetic 
high-fat fed mice, despite increased weight gain when compared to their counterparts fed the 
standard diet. 
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 Both diabetic groups exhibited severe hyperglycemia, but diabetic mice fed the high-fat 
diet had significantly lower blood glucose levels than diabetic mice fed the standard diet at 
throughout the duration of the study. Although hyperglycemia was not severe enough to be 
defined as overt diabetes, glucose levels were elevated in NdHF compared to NDStd, suggesting 
nondiabetic mice fed the high-fat diet may be in a pre-diabetic state. As expected in STZ-induced 
diabetic mice, insulin levels were significantly lower in both diabetic groups compared to the 
nondiabetic groups on the equivalent diet. High-fat feeding induced hyperinsulinemia in 
nondiabetic mice, providing additional evidence to suggest that high-fat fed nondiabetic mice 
have disrupted insulin and glucose homeostasis, consistent with pre-diabetes. 
 
Sensorimotor Behavior is Altered by High-Fat Feeding 
  As reported in Chapter 1, our previous data reveals that a high-fat diet fed to STZ-
induced diabetic C57BL/6 mice strongly alters phenotype of neural symptoms by inducing a 
robust mechanical hyperalgesia instead of the mechanical insensitivity that normally develops in 
this model. We have not confirmed specific mechanisms that drive high-fat diet-induced 
mechanical hyperalgesia, thus it is important to examine the potential role of mitochondrial 
dysfunction this novel, diet-induced behavioral phenotype. 
 
Mitochondrial Respiration 
  To determine the effect of diabetes and a high-fat diet on mitochondrial function in mice 
that exhibit signs of neuropathy, mitochondrial respiration was assessed in the lumbar DRG and 
peripheral axonal processes. Basal respiration was significantly lower in diabetic mice fed the 
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standard diet compared to diabetic mice fed the high-fat diet (Figure 1A). There were no 
significant differences among groups in leak dependent respiration (Figure 1B) or maximal 
respiration (Figure 1C). Spare respiratory capacity was higher in diabetic mice fed the standard 
diet compared to nondiabetics consuming the equivalent diet (Figure 1D). The high-fat diet did 
not alter mitochondrial respiration in nondiabetic or diabetic mice (Figure 1A-D). Despite 
deficits in basal respiration, no other respiration parameters were diminished in diabetic mice fed 
the standard diet, suggesting diabetes had a relatively mild effect on mitochondrial respiration. 
  
Expression of Proteins Involved in Mitochondrial Function  
 Western blots were performed on DRG and peripheral axon lysates to determine if 
diabetes or high-fat feeding had an effect on the expression of oxidative phosphorylation proteins 
or other proteins that affect mitochondrial function or biogenesis. Expression of subunits from 
oxidative phosphorylation complexes I, II, or V were not altered by diabetes or the high-fat diet 
(Figure 2A-B, D). Uncoupling protein 2 (UCP2) expression was also not different among groups 
(Figure 3A). In contrast, Complex III subunit Core-2 (Figure 2C) and voltage dependent anion 
channel (Figure 3B, VDAC) were significantly increased in diabetic mice compared to 
nondiabetic mice fed the standard diet.  A significant increase in both of these proteins in DbStd  
vs. NdStd suggests diabetes may stimulate mitochondrial biogenesis in face of impaired basal 
mitochondrial respiration. 
 However, there were no significant differences among groups in expression of 
peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) or  
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Figure 1: Mitochondrial respiration measurements in freshly isolated lumbar dorsal root 
ganglia. 
Twelve lumbar DRG and their peripheral processes were freshly isolated at 8 weeks post-STZ 
and high-fat diet. Whole intact DRG with processes were placed into the respiration chamber. A) 
Basal respiration was measured before addition of drugs or inhibitors. B) Leak dependent 
respiration was measured after oligomycin injection. C) Maximal respiration in response to 
FCCP injection. D) Spare respiratory was calculated by subtracting basal O2 flux from maximal 
O2 flux. O2 flux was normalized to total protein and VDAC band intensity from Western blot 
(VDAC/actin). Data are presented as means ± SEM (n = 8-10 mice per group) . *P < 0.05. 
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Figure 2: Expression of mitochondrial oxidative phosphorylation proteins in the lumbar 
dorsal root ganglia. 
Mitochondrial oxidative phosphorylation proteins were measured by Western blot. Tissues were 
harvested at 8 weeks post-STZ and high-fat diet. Representative images and quantification of 
subunits of mitochondrial oxidative phosphorylation complexes. A) Complex I, B) Complex II, 
C) Complex III, and D) Complex V. Band intensities were normalized to actin. Data are 
presented as means ± SEM (n = 8-10 mice per group) . *P < 0.05. 
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Figure 3: VDAC and UCP2 expression in the lumbar dorsal root ganglia. 
Proteins were measured by Western blot. Tissues were harvested at 8 weeks post-STZ and high-
fat diet. Representative images and quantification of group means for UCP2 (A) and VDAC (B). 
Band intensities were normalized to actin. Data are presented as means ± SEM (n = 8-10 mice 
per group). No significant differences among groups. 
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Figure 3 
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peroxisome proliferator- activated receptor gamma coactivator 1-beta  (PGC-1β) which are 
transcriptional coactivators that regulate mitochondrial biogenesis and function (Figure 4A-B). 
 Furthermore, there was no significant effect of diabetes or high-fat feeding on activation 
of proteins indirectly involved in mitochondrial biogenesis via PGC-1α activation or inhibition, 
including NAD-dependent deacetylase sirtuin-1 (Sirt 1, Figure 4C), activated protein kinase B 
(phospho Akt, Figure 5A), or 5' adenosine monophosphate-activated protein kinase (AmpK, 
Figure 5C) Mammalian target of rapamycin (mTor) activation is inhibited during nutrient 
starvation and its inhibition leads to autophagy. In addition, activated mTor plays an important 
role in the PGC-1α complex that is essential for activating mitochondrial DNA synthesis. 
Despite significant weight loss in both diabetic groups, mTor activation was not altered in 
diabetic mice fed the standard or high-fat diet (Figure 5B).  
 
Diabetic Animals Are in Ketoacidois 
 Diabetic and high-fat fed mice can develop ketosis due to increased fatty acid 
metabolism. Ketone bodies provide an alternative energy source and can affect mitochondrial 
function. Therefore, serum beta-hydroxybutyrate (β-HB) levels were quantified. Circulating β-
HB levels were significantly increased in both diabetic groups compared to their nondiabetic 
counterparts. DbHF mice did not have significantly higher β-HB levels than DbStd mice, but the 
lack of statistical significance was likely due to high variability in the DbHF group (Figure 6). β-
HB levels were not higher in high-fat fed nondiabetic mice compared to nondiabetic mice on the 
standard diet (Figure 6). The β-HB levels in both groups of diabetic mice were high enough to 
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Figure 4: Expression of proteins involved in mitochondrial biogenesis in the lumbar dorsal 
root ganglia. 
Proteins were measured by Western blot. Tissues were harvested at 8 weeks post-STZ and high-
fat diet. Representative images and quantification of group means for PGC-1α (A), PGC-1β, and 
Sirt 1 (C). Band intensities were normalized to actin. Data are presented as means ± SEM (n = 8-
10 mice per group). No significant differences among groups. 
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Figure 4 
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Figure 5: Expression of proteins involved in signaling pathways that affect mitochondrial 
density in the lumbar dorsal root ganglia. 
Proteins were measured by Western blot. Tissues were harvested at 8 weeks post-STZ and high-
fat diet. Representative images and quantification of group means for pAkt (A), pMtor, and (C) 
pAmpK. Band intensities for phosphorylated proteins were normalized to the total protein. Data 
are presented as means ± SEM (n = 8-10 mice per group). No significant differences among 
groups. 
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Figure 5 
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Figure 6: Serum β-hydroxybutyrate levels after 8 weeks of high-fat diet and/or diabetes. 
Data are presented as means ± SEM (n = 10-18 mice per group). **P < 0.01, ***P < 0.001.  
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Figure 6 
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indicate ketoacidosis and reduced blood pH, although these cut off values are not defined in 
rodents [214]. 
 Because transient receptor potential cation channel subfamily V member 1 (TRPV1), an 
ion channel that has been implicated in chronic pain conditions [215], responds to a drop in pH 
or heat [216, 217], and high-fat fed mice exhibit mechanical hyperalgesia, we examined the 
relationship between β-HB levels and sensorimotor behavior after 8 weeks of diabetes and/or 
high-fat feeding (behavioral data was collected and described in Chapter 2). There were no 
significant correlations between β-HB levels and percent paw withdrawal (Figures 7A, 7C, 7E, 
mechanical sensitivity) in the NdHF, DbStd, or DbHF groups. However, increased withdrawal 
latency in response to a thermal stimulus was positively correlated β-HB levels (Figure 7D) in 
DbStd.  β-HB levels were not correlated with thermal sensitivity in NdHF or DbHF (Figures 7B 
and 7F). NdHF mice do not display altered thermal sensitivity, thus we did not expect a 
significant correlation in this treatment group for this behavioral test (Figure 7B).   
 
β-Hydroxybutyrate treated cells 
  Because both diabetic groups had significantly increased serum β-HB levels (Figure 6) 
and β-HB has been shown to affect mitochondrial respiration [218], the effect of β-HB treatment 
on expression of mitochondrial oxidative phosphorylation proteins and VDAC in cultured SY5Y 
neurons was examined. Eight-hour β-HB treatment had no effect on mitochondrial oxidative 
phosphorylation proteins (Figure 8A-D) or VDAC expression (Figure 8E) compared to untreated 
control cells.    
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Figure 7: Correlations between serum β-hydroxybutyrate level and behavioral signs of 
neuropathy. 
Correlations between β-hydroxybutyrate level and percent paw withdrawal, a measure of 
mechanical sensitivity (A, C, E) and withdrawal latency, a measure of thermal sensitivity (B, D, 
F)  in NdHF (A-B),  DbStd (C-D), and DbHf   (E-F). n = 8-18 mice per group for correlations 
with mechanical sensitivity (A, C, E) and n = 3-8 mice per group for correlations with thermal 
sensitivity (B, D, F). NdHF and DbHF exhibit mechanical hyperalgesia while DbStd mice 
exhibit mechanical insensitivity. DbStd and DbHF display thermal hypoalgesia. Thermal 
hypoalgesia was significantly correlated with β-hydroxybutyrate levels in DbStd: *P < 0.05.  
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Figure 8: Expression of mitochondrial proteins in control and β-hydroxybutyrate treated 
SH-SY5Y neuronal cells.  
Cells were harvested after 8 hour treatment in DMEM supplemented with 5 mM glucose 
(control) or 5 mM glucose and 5 mM β-hydroxybutyrate (β-HB treated). Proteins were measured 
by Western blot. Representative images and quantification of group means for subunits of 
mitochondrial oxidative phosphorylation complexes: A) complex I, B) complex II, C) complex 
III, and D) complex V, and VDAC, a mitochondrial protein that is not involved in oxidative 
phosphorylation (E). Data are presented as means ± SEM (n = 5 cell lysates per group). No 
significant differences. 
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Figure 8 
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5. Discussion  
Recent evidence suggests mitochondrial dysfunction may play an important role in the 
pathogenesis underlying diabetic neuropathy . Here, for the first time, we report mitochondrial 
respiration data collected from undisrupted freshly isolated lumbar DRG and peripheral axonal 
processes. All previous reports documenting mitochondrial dysfunction in animal models of 
diabetic neuropathy have performed experiments on primary DRG cultures, isolated 
mitochondria, or DRG homogenates from diabetic animals [20, 22, 63, 64, 66, 68, 73]. In effort 
to improve upon these experiments and more closely emulate the in vivo environment, we 
measured mitochondrial respiration in whole tissue (lumbar DRG and peripheral axonal 
processes) immediately following dissection.  In addition, for the first time, mitochondrial 
respiration was assessed in the DRG and axonal processes in high-fat fed mice. The use of a 
high-fat diet in conjunction with type I diabetes is a novel, clinically relevant model of diabetic 
neuropathy and previous studies of mitochondrial dysfunction in diabetic neuropathy have not 
incorporated diet into mitochondrial assessments. 
 
Diabetes Impairs Some Aspects of Mitochondrial Respiration and Alters the Mitochondrial 
Proteome 
Our results reveal that after 8 weeks of diabetes, basal mitochondrial respiration was 
decreased in the lumbar DRG and peripheral axonal processes from diabetic mice fed a standard 
diet compared to their nondiabetic counterparts. Importantly, results from our experiments using  
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this novel methodology are consistent with previous studies that report mitochondrial respiration 
deficits in DRG from diabetic mice [20, 63, 64, 66].  
 In contrast, spare respiratory capacity and expression of mitochondrial proteins VDAC 
and Complex III subunit Core-2 were increased in diabetic mice fed the standard diet compared 
to nondiabetic mice fed the standard diet. VDAC is an ion channel protein that is abundantly 
present on the mitochondrial membrane [219]. Thus, increased VDAC expression may indicate 
increased mitochondrial mass. Complex III subunit Core-2 is a subunit of the mitochondrial 
oxidative phosphorylation Complex III. Increased expression of specific mitochondrial oxidative 
phosphorylation proteins suggest increased mitochondrial mass or an isolated increase in a 
specific oxidative phosphorylation protein in effort to preserve respiration despite mitochondrial 
damage. These results oppose data from several previous studies that indicate mitochondrial 
oxidative phosphorylation protein expression is reduced in DRG from diabetic rodents [63, 64, 
66, 220]. However, the current study was only 8 weeks in duration and mitochondrial function 
was in examined in mice rather than rats.  
Spare respiratory capacity is calculated by subtracting the maximal mitochondrial oxygen 
flux rate from the basal mitochondrial oxygen flux rate. Spare respiratory capacity represents the 
capability of mitochondria to increase respiration beyond basal respiration. Typically, damaged 
mitochondria exhibit reduced maximal respiration and/or reduced spare respiratory capacity. 
Therefore, it is surprising that diabetic mice fed the standard diet had significantly higher spare 
respiratory capacity compared to nondiabetic mice fed the standard diet. However, it is important 
to note that in all groups except NdStd, spare respiratory capacity was negative, indicating 
maximal respiration was lower than basal respiration.  
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When the experimental conditions and drug concentrations are optimized, the maximal 
oxygen flux rate is usually greater than or equal to the basal oxygen flux rate in control tissue 
(NdStd in this case), resulting in zero or positive spare respiratory capacity. A noteworthy caveat 
is the fact that spare respiratory capacity was positive in the majority of DbStd mice while spare 
respiratory capacity was negative in the majority of the mice from the other three groups. 
Although careful efforts and numerous pilot experiments were performed to optimize the assay 
conditions for whole undisrupted tissue, it is possible the FCCP concentration was not potent 
enough to elicit maximal respiration. Because the diabetic animals fed the standard diet are lower 
in body weight and have smaller tissue volume, the FCCP potentially had a more potent effect on 
the DbStd tissue, while the FCCP injection had a less potent effect on the typically larger tissue 
of animals from the NdStd, NdHF, or DbHF groups. This caveat introduces uncertainty, 
suggesting that true maximal respiration was not achieved in experiments in animals from all 
groups, thus deeming the maximal oxygen flux rate and spare respiratory capacity data 
inconclusive. If the FCCP potency were sufficient to stimulate maximal respiration in variable 
tissue volumes from animals in all groups, perhaps the spare respiratory capacity would be 
diminished in DbStd compared to NdStd.  
In the current study, mitochondrial respiration was normalized to total protein to correct 
for differences in tissue volume and subsequently normalized to VDAC expression to account 
for mitochondrial density. When the VDAC normalization was removed and mitochondrial 
respiration was normalized to total protein only, there were no significant differences among 
groups in basal mitochondrial respiration (NdStd ± 191.5,  NdHF 196.3 ± 24.6,  DbStd 193.5 ± 
18.1, DbHF 172.3 ± 12.8 pmols O2 sec-1 mg protein-1). This suggests that the total amount of 
basal mitochondrial respiration occurring in the tissue is not altered in diabetic mice, but the 
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amount of respiration being performed by each mitochondrion may be diminished. Reduced 
basal mitochondrial respiration suggests diabetes induced mitochondrial stress while increased 
VDAC and Complex III subunit Core-2 expression indicates potential mitochondrial biogenesis. 
Together, these results suggest that diabetes negatively impacts mitochondrial function and 
compensatory mitochondrial biogenesis may occur to maintain mitochondrial respiration. 
The high-fat diet did not appear to significantly impact mitochondrial function in 
nondiabetic or diabetic mice as there were no other differences among other groups in 
mitochondrial respiration or mitochondrial protein expression. The effects of high-fat feeding on 
mitochondrial function in sensory neurons have not been documented in the literature. 
 
Expression of Proteins Related to Mitochondrial Biogenesis and Mitochondrial Function are Not 
Altered by Diabetes or a High-Fat Diet 
 Diabetes and high-fat feeding have each been purported to alter expression of other 
proteins that play an important role in mitochondrial function and/or mitochondrial biogenesis. 
In this study, neither diabetes nor the high-fat diet had an effect on UCP2, PGC-1α, PGC1β, or 
Sirt 1 expression, or Akt, AMPK, or mTor activation in the lumbar DRG and peripheral axonal 
processes.  
 UCP2 is a mitochondrial uncoupling protein that resides in the inner mitochondrial 
membrane, facilitates proton return from the outer to inner mitochondrial membrane, and 
separates oxidative phosphorylation from ATP synthesis while dissipating energy as heat [221]. 
Increased UCP2 expression can cause increased proton leak from the outside into the 
mitochondria and may contribute to increased leak dependent respiration. However, since there 
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were no differences among groups in leak dependent respiration, it is not surprising that UCP2 
expression was not affected by diabetes or the high-fat diet. 
 Because changes in mitochondrial respiration and the mitochondrial proteome suggest 
that diabetes stimulated mitochondrial biogenesis in mice fed the standard diet, we investigated 
the effect of diabetes and the high-fat diet on expression of proteins that play an important role in 
mitochondrial biogenesis and autophagy. Figure 9 illustrates the relationships between PGC-1α, 
Sirt 1, Akt, and mTor with notable convergence on PGC-1α activation, mitochondrial biogenesis, 
and autophagy. 
 PGC-1α and PGC-1β belong to a family of transcription coactivators that play a central 
role in the regulation of cellular energy metabolism [222]. PGC-1α interacts with transcription 
factors and/or nuclear receptors to stimulate mitochondrial biogenesis, hepatic gluconeogenesis, 
adaptive thermogenesis, and/or fatty acid and glucose metabolism [222]. Although the functions 
of PGC-1β are not as well documented as PGC-1α, its functions are similar and participates with 
PGC-1α in coordinated coactivation of metabolically relevant transcription factors to stimulate 
mitochondrial biogenesis and fatty acid oxidation.  PGC-1α and PGC-1β function is 
compromised in obesity, insulin resistance, and type 2 diabetes [223]. AMPK acts as an energy 
sensor and key regulator of cellular energy homeostasis by responding to an increased 
AMP/ATP ratio. AMPK is activated by phosphorylation when ATP is depleted and among other 
functions, phosphorylated AMPK activates PGC-1α [224]. The AMPK/ PGC-1α signaling axis is 
decreased in hyperglycemia and recent evidence suggests that neuronal dysfunction in diabetic 
neuropathy is associated with mitochondrial dysfunction due to impaired AMPK/ PGC-1α 
signaling [224]. Chowdhury et al. reported reduced PGC-1α expression and reduced AMPK  
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Figure 9 
 
 
Figure 9: Schematic illustrating activation and inhibition of proteins that activate PGC-1α. 
This content in this figure was developed by Russell Swerdlow and creatively enhanced by 
Stanton Fernald. 
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activation in DRG from STZ-induced diabetic rats and db/db mice [64]. However, it is important 
to note that in Chowdhury et al., there were no changes in AMPK activation or PGC-1α after 4 
weeks of diabetes, and deficits in these proteins were not seen until after 8 weeks of diabetes 
[64]. In the current study, there were no differences among groups in PGC-1α and PGC-1β 
expression or AMPK activation in the DRG after 8 weeks of diabetes. In addition, reduced basal 
mitochondrial respiration accompanied by increased mitochondrial proteins in diabetic mice fed 
the standard diet suggested potential compensatory mitochondrial biogenesis.  Thus its plausible 
to expect increased PGC-1α expression in DbStd compared to NdStd. Perhaps these tissues were 
assessed on the cusp of a time point when subtle changes begin to appear in these proteins and 
any changes were too subtle to be detected by Western blot at this time point. Alternatively, 
PGC-1α expression may have increased earlier in time course of diabetes in order to trigger 
compensatory mitochondrial biogenesis and may have returned to normal levels by the time 
tissues were harvested after 8 weeks of diabetes.    
 Sirt 1 is a nutrient-sensing histone deacetylase that is activated by a rising NAD+/NADH 
ratio and plays an important role in regulating metabolic function in many tissues [225]. In 
adipose tissue, Sirt 1 protects from obesity and inflammation under normal feeding conditions 
[225], is a positive regulator of insulin secretion [226] and autophagy [227], and has been 
identified as a potential therapeutic target for type 2 diabetes and diabetic complications [228]. 
Sirt 1 deacetylates, and thereby activates PGC-1α and indirectly stimulates mitochondrial 
biogenesis [229]. Sirt 1 is expression and activity is reduced in liver adipose tissue of high-fat 
fed rodents [225]. Furthermore, a Sirt1 genetic variant is associated with reduced insulin 
sensitivity and is a type 2 diabetes risk in Pima Indians [230]. Although Sirt-1 expression was 
slightly reduced in the DRG of high-fat fed nondiabetic and diabetic mice in the current study, 
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these differences did not reach statistical significance in this cohort of animals. If diabetes and 
high-fat feeding were greater than 8 weeks in duration, significant changes in Sirt-1 expression 
may have been apparent. 
 Akt is a serine/threonine kinase that plays a pivotal role in several cellular processes 
including cell proliferation and migration, apoptosis, and glucose metabolism. Akt is a 
downstream effector of PI 3-kinsases and is a key protein in the insulin-signaling pathway in 
peripheral tissues and neurons [231, 232]. The active form of Akt is phosphorylated (pAkt) on 
serine reside 473, and Akt activation is reduced in insulin resistant states [132]. In fact, insulin-
stimulated Akt activation is blunted in DRG neurons from diabetic mice [132]. Insulin signaling, 
via downstream Akt activation is important for maintenance of mitochondrial function in 
neurons [21, 66]. Because high-fat fed nondiabetic mice exhibited hyperinsulinemia and 
hyperglycemia in the current study, we suspected these mice were mildly insulin resistant and 
hypothesized Akt activation might be blunted in the DRG. There were no significant differences 
among groups in Akt activation in the DRG. However, Grote and colleagues [132] found that 
Akt activation was assessed in primary cultured DRG after insulin stimulation while there was 
no insulin stimulation and the DRG were not cultured in the current study.   
 mTor is a serine/threonine protein kinase that responds to nutritional status, growth factor 
and stress signals, and plays a key role at the interface of pathways that regulate the balance 
between cell growth and autophagy . When activated, mTor associates with other proteins and 
can be present in one of two complexes (mTORC1 or mTORC2).  Nutrient starvation or reduced 
growth factor availability can activate mTor and mTORC1 complex formation, and subsequently 
induce autophagy [233]. Akt is upstream and positively regulates mTor while active AMPK 
inhibits mTORC1. Because mTORC1 is inhibited by oxidative stress and mitochondrial 
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dysfunction, it has been suggested that mTORC1 may be involved in the mechanism by which 
damaged mitochondria induce autophagy (9, 44). In the present study, it is possible that mTor 
activation was altered by nutrient starvation in diabetic mice fed the standard diet or by the 
downstream effects of insulin resistance in nondiabetic high-fat fed mice. Based on the 
nutritional status of these groups of animals, we might expect increased mTor activation and 
increased autophagy in DbStd and/or reduced mTor activation and reduced autophagy in NdHF. 
However, increased mitochondrial proteins in diabetic mice fed the standard diet would not be 
congruent with increased autophagy, unless it was accompanied by mitochondrial biogenesis. In 
the current study, there were no differences among groups in phosphor mTor expression, thus the 
high-fat diet, nor diabetes impacted mTor activation. 
 
Increased β-Hydroxybutyrate Levels are Not Correlated with Mechanical Hyperalgesia 
 According to cut-off values for human ketoacidois and previous studies in rodents, both 
diabetic groups exhibited increased serum β-HB levels, indicative of diabetic ketoacidosis [214]. 
Because blood pH is lowered in the ketoacidotic state [214] and TRPV1, an ion channel that has 
been implicated in chronic pain states responds to reductions in pH [215], we hypothesized 
increased β-HB levels might be correlated with mechanical hyperalgesia in the NdHF and DbHF 
group. However,  β-HB levels were not significantly increased in NdHF, nor was β-HB 
correlated with mechanical hyperalgesia in either group. Although we did not expect β-HB levels 
to be correlated with thermal hypoalgesia, withdrawal latency was positively correlated with β-
HB levels in DbStd but not DbHF. However, specific to the  β-HB correlation with thermal 
sensitivity for DbStd, there were only three mice in the DbStd group. Therefore, the significant 
correlation between β-HB level and thermal hypoalgesia in the DbStd group should be 
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interpreted with caution. Mice in the DbHF group also exhibit thermal hypoalgesia and elevated  
β-HB, but there was not a significant correlation between these variables in the DbHF group (p = 
0.09). However, the P-value suggests a trend toward a positive correlation between withdrawal 
latency and β-HB in DbHF, would is consistent with the effect as observed in DbStd. Although 
DbStd and DbHF exhibit opposite behavioral responses to a mechanical stimulus (insensitivity in 
DbStd and hyperalgesia in DbHF), both groups display thermal hypoalgesia. We expect that β-
HB level is positively correlated with withdrawal latency due to severity of diabetes or 
hyperglycemia. DbStd mice had consistently higher glucose levels than DbHF.       
  
β-Hydroxybutyrate Treatment Does Not Alter Expression of Mitochondrial Proteins in Cultured 
Neurons 
 Recent evidence indicates circulating ketones can impact mitochondrial respiration, 
mitochondrial biogenesis, and the mitochondrial proteome [218, 234].  We hypothesized that 
ketosis may alter mitochondrial respiration and protein expression in neurons. Consequently, we 
performed an experiment on cultured SY5Y neurons to determine if treatment with β-HB altered 
mitochondrial protein expression. There were no significant differences in expression of VDAC 
or subunits of mitochondrial oxidative phosphorylation complexes in control versus 8 hour β-HB 
treated cells. Perhaps the result would be different had we used primary cultures from 
nondiabetic and diabetic mice or if β-HB exposure was chronic rather than acute. Although both 
diabetic groups had elevated β-HB compared to their nondiabetic counterparts, the high-fat diet 
did not exacerbate ketosis.  
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Summary and Conclusions 
 In summary, diabetes significantly reduced basal mitochondrial respiration with a 
concomitant increase in VDAC and Complex III subunit Core-2 expression in DRG and 
peripheral axonal processes isolated from mice fed a standard diet. Surprisingly, were no 
changes in mitochondrial respiration or mitochondrial protein expression in high-fat fed 
nondiabetic or diabetic mice. If altered mitochondrial function in diabetic mice is primarily 
mediated by hyperglycemia, diabetic mice fed the high-fat diet may be partially protected from 
these effects via less severe hyperglycemia resulting from lower dietary carbohydrate content 
compared to diabetic mice fed the standard diet.  
 Taken together, these data suggest subtle mitochondrial dysfunction and potential 
compensatory mitochondrial biogenesis occurs after 8 weeks of STZ-induced diabetes and high-
fat feeding does not alter these parameters. These data support previous results that indicate 
diabetes-induced deficits in mitochondrial respiration.  This work has a significant impact on the 
diabetic neuropathy field as it employed novel methodology by measuring mitochondrial 
respiration in freshly isolated undisrupted DRG and peripheral axonal processes. In addition, for 
the first time, mitochondrial function was assessed in STZ-induced type 1 diabetic mice fed a 
high-fat diet.  In light of the recent clinical evidence identifying dyslipidemia as an independent 
risk factor for the development of diabetic neuropathy, this type 1 diabetic/high-fat combination 
is a novel and clinically relevant model that is useful for studying diabetic neuropathy. Because 
mitochondrial dysfunction is subtle in the DRG and significant mitochondrial impairment may 
also occur in axonal transport and trafficking, future studies should investigate the effect of 
diabetes on mitochondrial function in peripheral nerves responsible for innervating the lower 
extremities.    
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CHAPTER 4 
The Role of Inflammation in High-Fat Diet-Induced Hyperalgesia 
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1.  Abstract 
Previous data reveals that a high-fat diet fed to STZ-induced diabetic C57BL/6 mice 
strongly alters the neuropathy phenotype by inducing mechanical hyperalgesia instead of 
insensitivity that normally develops in this model. HF fed nondiabetic mice also develop 
mechanical hyperalgesia. Pro-inflammatory cytokines and chemokines contribute to the 
development of nociception, including diabetic neuropathy. A high-fat diet induces pro-
inflammatory cytokine production, suggesting diet-induced inflammation may drive mechanical 
hyperalgesia. Additionally, increased cytokine and chemokine levels are associated with glial 
activation in the spinal cord, suggesting neural inflammation and glial activation are important 
central nervous system mediators of pain.  The purpose of this study was to determine if a high-
fat diet increases induces inflammation in the spinal cord or peripheral tissues. We hypothesized 
that a high-fat diet induces central and/or peripheral inflammation in conjunction with glial 
activation in the spinal cord, thus resulting in chronic mechanical hyperalgesia.  Following STZ 
or vehicle injection, male C57Bl/6 mice were fed a standard or high-fat diet for 8 weeks.  
Consistent with previous findings in this insensate model of diabetic neuropathy, diabetic mice 
fed the standard diet exhibited mechanical insensitivity compared to nondiabetic mice fed the 
standard diet. In contrast, high-fat-fed nondiabetic and diabetic mice developed robust 
mechanical hyperalgesia. Surprisingly, there were no significant differences among groups in 
cytokines or chemokines: Il-1α, Il-1β, Il-2, TGFβ, Il-10, Il-12p70, Il-17, MCP-1, or TNF-α in the 
lumbar spinal cord.  Furthermore, microglial activation was not increased by diabetes or a high-
fat diet. Although TNF-α levels were not altered in peripheral tissues, serum TNF-α levels were 
lower in high-fat-fed nondiabetic mice and standard-fed diabetic mice compared to nondiabetic 
mice fed the standard diet. In conclusion, high-fat diet-induced mechanical hyperalgesia was not 
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accompanied by spinal or peripheral inflammation or microglial activation after 8 weeks of high-
fat feeding. Although inflammation was not apparent at week 8, it is plausible that the 
inflammatory response occurred at an earlier time point near the initiation of mechanical 
hyperalgesia. Therefore, future experiments will examine spinal and peripheral inflammation 
after 4 weeks of high-fat feeding which is near the onset of behavioral changes in mechanical 
sensitivity. 
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2. Introduction 
 There are a number of proposed mechanisms that contribute to diabetic neuropathy but 
no information is available as to why diabetic patients either develop painful symptoms (painful 
neuropathy) or a loss of sensation (insensate neuropathy). Emerging studies now suggest that 
spinal cord inflammation plays a key role in chronic pain. Increased pro-inflammatory cytokine 
and chemokine synthesis is associated with glial activation in the spinal cord, suggesting that 
neural inflammation and glial activation may collaboratively increase nociception and lead to 
chronic pain. 
 It has been well documented that STZ-induced diabetic C57Bl/6 mice develop a 
moderate insensate neuropathy characterized by a mild reduction in mechanical sensitivity after 
4 weeks of diabetes [181-183, 189, 235]. In striking contrast, STZ-diabetic mice fed a high-fat 
diet display a painful diabetic neuropathy phenotype as opposed to the insensate phenotype 
typically observed in this strain  (Reviewed in Ch.2 [30]). Interestingly, the high-fat diet induced 
a robust mechanical hyperalgesia; mechanical sensitivity was increased by 35% and 45%, 
respectively, in nondiabetic and diabetic mice compared to their counterparts fed a standard diet 
(Reviewed in Ch.2 [30]). This finding is particularly important because it suggests that diet 
modulates diabetic neuropathy phenotype in rodents and may shed light on why some patients 
experience insensate symptoms while others have painful symptoms. In addition, this data 
supports previous reports that a high-fat diet can induce neuropathy in nondiabetic mice [5, 23]. 
Little is known about mechanisms contributing to high-fat diet-induced painful 
neuropathy, but a recent study indicates that an extract from the Artemisia plant (known for its 
anti-inflammatory and anti-nociceptive properties) alleviates high-fat diet induced mechanical 
hyperalgesia and reduces 12/15 lipoxygenase (regulates pro-inflammatory cytokine production) 
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upregulation, suggesting that inflammation may play a role in high-fat diet induced neuropathy 
[190]. Pro-inflammatory cytokines and chemokines have been widely implicated in chronic pain 
and are thought to contribute to the central sensitization that results in mechanical hyperalgesia 
[198-201]. For example, interleukin-6 (IL-6) via its actions in the dorsal horn induces allodynia 
and hyperalgesia [236], and interleukin 1-beta (IL1-β) enhances the spinal release of substance P 
[237]. In addition, inflammation can induce a phenotypic switch in A-β fibers so that they 
acquire properties of pain-sensing C-fibers, thus enhancing spinal synaptic transmission and 
contributing to hypersensitivity [199].  
In rodent models of neuropathic pain, increased pro-inflammatory cytokine and 
chemokine synthesis is associated with glial activation in the spinal cord, suggesting that neural 
inflammation and glial activation are important mediators within central nervous system 
associated with pain [238-242].  Activated glia are abundant sources of pro-inflammatory 
cytokines and can modify synaptic transmission and nociception via interactions with neurons 
[206-210]. In addition, glial activation has been shown to be necessary and sufficient to create 
pathological pain in laboratory animals [243-245] and microglia are activated in the spinal dorsal 
horn of STZ-induced diabetic rats that display mechanical hyperalgesia [246].  
Importantly, obesity is associated with chronic low-grade inflammation [79, 80], and a 
high-fat diet increases the pro-inflammatory cytokines IL1-β, tumor necrosis factor alpha (TNF-
α), and IL1-6, and stimulates inflammatory signaling in adipose, serum, liver, and brain [124, 
202-205]. Along with glia and macrophages [206-211], adipose is an important source of pro-
inflammatory cytokines that may upregulate cytokine production due to increased adipose 
resulting from a high-fat diet [124, 202].  
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Although high-fat diet induced neuropathy has been reported in the literature, only 
Obrosova et al. has investigated potential mechanisms underlying this phenomenon and suggests 
inflammation may play a role in high-fat diet induced mechanical hyperalgesia [190]. We 
initially postulated mitochondrial dysfunction might contribute to high-fat diet induced 
mechanical hyperalgesia, but results from our previous study (reviewed in Chapter 3) suggest 
mitochondrial dysfunction is likely not a key mechanism underlying diet-induced behavioral 
changes in nondiabetic or diabetic mice. Thus, additional investigation is needed to identify 
putative cellular changes associated with high-fat diet induced neuropathy in effort to identify 
potential mechanisms. Here, we report the effects of a high-fat diet on inflammatory factors in 
the spinal cord and peripheral tissues and microglial activation in the spinal cord in nondiabetic 
and diabetic mice.   
 
3. Experimental Procedures 
Animals and Diet  
 In this study, animal age, housing conditions and diet composition were the same as 
described in Chapters 2 and 3. Seven week-old male C57Bl/6 mice were purchased from Charles 
River (Wilmington, MA), housed two mice per cage under pathogen free conditions, and placed 
on a 12:12h light/dark cycle in the research support facility at the University of Kansas Medical 
Center. All animals had ad libitum access to food and water and were fed a standard diet (14% 
kcals from fat) or high-fat diet (54% kcals from fat). Animals in the high-fat diet group were fed 
the standard diet for 1 week prior to STZ-injection and 1 week after STZ-injection. The high-fat 
groups began the high-fat diet 1 week after STZ-injection. It is noteworthy to mention that mice 
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began the high-fat diet 3 hours post STZ-injection in experiments described in Chapters 2 and 3 
rather than 1 week post STZ-injection. We delayed high-fat diet initiation to 1 week post-STZ in 
effort to cause less metabolic stress and reduce mortality in the diabetic high-fat group. All 
protocols and procedures were approved by the University of Kansas Medical Center Animal 
Use and Care Committee.                                      
 
Diabetes Induction and Glucose Measurement 
 The diabetes induction, body weight, and glucose measurement protocols used in these 
experiments were identical to the protocols described in Chapters 2 and 3. STZ-injection was 
used to induce diabetes in 8-week old male C57Bl/6 mice. Nondiabetic mice were injected with 
vehicle buffer.  All mice were fasted for 3 hours pre and post injection. Body weight and blood 
glucose were monitored weekly and criteria for inclusion in the diabetic groups were defined as 
described in Chapters 2 and 3. Treatment groups are abbreviated throughout as follows: 
nondiabetic standard diet (NdStd); nondiabetic high-fat diet (NdHF); diabetic standard diet 
(DbStd); and diabetic high-fat diet (DbHF). 
 
Behavioral Test for Mechanical Sensitivity  
 Mechanical sensitivity was assessed at baseline (wk 0, immediately before STZ-
injection) and every other week thereafter using the same procedures as described in Chapters 2 
and 3. Mice were acclimated to the testing apparatus before baseline testing. Subsequently, mice 
were placed on an elevated wire mesh screen, enclosed individually in a small clear plastic cage, 
and allowed to acclimate on the table for 30 minutes before the test. Mechanical sensitivity was 
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assessed using 12 applications of 1.4 gram Semmes-Weinstein von Frey monofilament to the 
hindpaw footpads. The total of 12 applications was used to calculate mean percent withdrawal 
per mouse and used to calculate group means for each testing week.  
 
Protein Extraction and Quantification of Cytokines and Chemokines  
 Cytokines and chemokines most frequently associated with inflammatory pain and excess 
dietary fat intake were quantified in the lumbar spinal cord and peripheral tissues. At 8 weeks 
post-STZ (or vehicle) injection, mice were anesthetized with isofluorane and decapitated. 
Lumbar spinal cord, sciatic nerves, gastrocnemius, and hindpaw plantar skin were dissected, 
snap frozen in liquid nitrogen, and stored at -800 C until protein extraction was performed. Blood 
was collected from the decapitation pool, clotted for 30 minutes on ice, and centrifuged for 15 
minutes at 3,000 x g. Serum was removed and stored at -80oC until analyzed for TNF-α.  Lumbar 
spinal cord was homogenized with cell lysis buffer containing PBS at pH 7.4, 2 mM PMSF, and 
1 µg/ml of each protease inhibitor (aprotinin, antipain, leupeptin, and pepstatin A). Sciatic nerves 
were sonicated and gastrocnemius and hindpaw plantar skin were homogenized with cell lysis 
buffer (137 mM NaCl, 20 mM Tris [pH 8.0], 1% NP40, and 10% glycerol) containing protease 
inhibitors (0.5 mm sodium vanadate, 1 µg/ml leupeptin, 10 µg/ml aprotinin, and 1 mM PMSF). 
Following homogenization, protein was extracted while tissue lysates were kept on ice for 1 hour 
and vortexed every 10 minutes. Samples were then centrifuged at 10,000 g for 10 minutes at 40 C 
and the protein concentration of the supernatant was measured using the Bio-Rad protein assay 
based on the Bradford method (Bio-Rad, Hercules, CA). Cytokines and chemokines in the 
lumbar spinal cord were quantified using the SearchLight Proteome Array (Aushon Biosystems, 
Billerica, MA). The Search Light Proteome Array is a multiplexed sandwich ELISA that was 
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customized to contain nine capture antibodies specific to IL-10, IL-12p70, IL-17, 1L-1α, 1L-1β, 
IL-2, MCP-1, TNF-α, IL-1β and TGF-β. In addition, TNF-α levels in the serum and sciatic 
nerve, gastrocnemius, and hindpaw plantar skin homogenates were quantified using a mouse 
TNF-α ELISA kit (eBioscience, San Diego, CA). 
 
Immunohistochemistry for Microglial activation 
 Microglial activation in the lumbar spinal dorsal horn was assessed using an antibody to 
Iba-1 (Wako Chemicals, Richmond, VA). Mice were deeply anesthetized with Avertin (1.23% 
v/v tribromoethanol; 2.5% tert-amyl alcohol; 200µl/10 g body weight) and transcardially 
perfused with 4% paraformaldehyde. The spinal cord was dissected, post-fixed overnight in 4% 
paraformaldehyde, rinsed in PBS (pH 7.4), and cryoprotected in 30% sucrose. After freezing in 
OCT, spinal cords were sectioned on a cryostat at 20 µm and mounted on Superfrost Plus slides 
(Fisher Scientific, Pittsburgh, PA) and stored at -20 0C. After thawing for 5 minutes a room 
temperature, sections were covered with blocking solution (0.5% porcine gelatin, 1.5% normal 
donkey serum, and 0.5% Triton-X in Superblock buffer; Pierce) for one hour and then incubated 
overnight with Iba-1 primary antibody at 40C. All sections were rinsed with PBST and then 
incubated with donkey anti-rabbit fluorochrome-conjugated secondary antibody (Santa Cruz, 
Santa Cruz, CA) diluted in PBS and blocking solution for 1 hr at room temperature. Following 
wash in PBS, slides were rinsed in slides were rinsed in deionized distilled H2O, coverslipped 
and stored at 4 0C.  Optical density thresholds were manually selected for positively labeled 
tissue and immunoreactivity was quantified in the dorsal horn according to Popovich et al [247]. 
Image analysis was performed using Nikon Elements software and microglial activation was 
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reported here as the proportional area of tissue occupied by Iba-1 positive cells within the dorsal 
horn after the optical threshold was applied.     
 
Statistics 
  Data were analyzed using a two-factor analysis of variance (ANOVA) or repeated 
measures ANOVA with Fisher’s test of least square difference post-hoc comparisons. Statistical 
significance was set at P < 0.05. 
 
4. Results and Figures 
Body Weight and Glucose 
 Body weight and glucose levels in this cohort of mice followed a nearly identical 
progression to the cohort of mice described in Chapter 2. Consistent with results reported in 
Chapter 2, both groups of diabetic mice weighed less compared to the nondiabetic mice on the 
equivalent diet (Figure 1A). Again, the diabetic high-fat-fed group gained weight while the 
diabetic mice fed the standard diet lost weight during the 8-week study (Figure 1A). In addition 
and similar to the cohort described in Chapter 2, nondiabetic mice fed the standard diet gained 
approximately 5g on average while nondiabetic high-fat-fed mice gained significantly more 
weight  (approximately 13 g on average) over the course of the 8 week study (Figure 1A).  
 Typical of STZ-induced diabetic mice and consistent with the previous cohort, both 
groups of diabetic mice were severely hyperglycemic compared to their nondiabetic  
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Figure 1: The effects of STZ-induced diabetes and high-fat diet on body weight and fasting 
blood glucose. 
Both diabetic groups display characteristic signs of diabetes including lower body weight and 
severe hyperglycemia compared to nondiabetic mice. High-fat fed mice gain more weight and 
have lower glucose levels than their standard diet counterparts. A) Body weight and B) Glucose. 
Data are presented as means ± SEM (n = 14 – 23 mice per group).  #P < 0.05, ##P  < 0.01 and  
###P < 0.001 for  NdStd vs. NdHF,  +++P < 0.001 for NdStd vs. DbStd, ***P < 0.001: NdHF vs. 
DbHF, and ^P< 0.05, and ^^^P < 0.001 for DbStd vs. DbHF. 
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Figure 1 
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counterparts (Figure 1B). Despite severe hyperglycemia, diabetic mice fed the high-fat diet had 
significantly lower glucose levels than diabetic mice fed the standard diet (Figure 1B). In  
contrast, nondiabetic mice fed the high-fat diet had higher glucose levels than nondiabetic mice 
fed the standard diet throughout the duration of the study, but this difference was only 
significantly different at week 5 (Figure 1B). Although the glucose levels in the NdHF group 
were very similar in this cohort and the previous cohort, glucose levels were significantly higher 
in NdHF vs. NdStd at weeks 5, 7, and 8 in the previous cohort (Chapter 2, Figure 1B). 
  
Nondiabetic and Diabetic Mice Fed a High-Fat Diet Develop Mechanical Hyperalgesia 
 Consistent with previous studies in this insensate model of diabetic neuropathy, STZ-
induced diabetic C57Bl/6 mice lose mechanical sensation when consuming a standard low-fat 
diet (Figure 2) [181-184]. In stark contrast and congruent with results reported in Chapter 2, 
STZ-induced diabetic C57Bl/6 mice develop robust mechanical hyperalgesia when fed a high-
fat diet (Figure 2) [30]. Nondiabetic mice fed the high-fat diet also developed robust mechanical 
hyperalgesia (Figure 2). Increased percent paw withdrawal reached statistical significance in 
DbHF at week 2 (compared to DbStd) and at week 4 in NdHF (compared to NdStd). 
Importantly, both NdHF and DbHF mice exhibited mechanical hyperalgesia and this behavioral 
phenotype was equivalent between these two groups (Figure 2). Thus, diabetes did not 
exacerbate high-fat diet induced mechanical hyperalgesia.  
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Figure 2: A High-fat diet induces mechanical hyperalgesia in nondiabetic and diabetic 
mice. 
Behavioral responses to repeated applications of a mechanical stimulus (1.4 g von Frey 
monofilament).   Data are presented as means ± SEM (n = 17 – 23 mice per group). #P  < 0.05 
and ##P < 0.01 for NdStd vs. NdHF, ++P < 0.01 for NdStd vs. DbStd, ^^P < 0.01 and  ^^^P < 
0.001 for DbStd vs. DbHF. 
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High-Fat Diet Induced Mechanical Hyperalgesia is Not Accompanied by Spinal Inflammation 
 We predicted high-fat diet induced mechanical hyperalgesia would be accompanied by 
spinal inflammation and microglial activation thus contributing to central sensitization and 
nociceptive behavior. Sensory neurons that innervate the lower limbs and hind paws synapse in 
the dorsal horn of the spinal cord, thus we specifically examined microglial activation in the 
lumbar spinal dorsal horn and inflammatory mediators in the lumbar spinal cord.  Results 
obtained from multiplex ELISA performed on lumbar spinal cord homogenates indicated no 
significant differences among groups in cytokines or chemokines: Il-1α, Il-1β, Il-2, TGF-β, Il-
10, Il-12p70, Il-17, MCP-1, or TNF-α (Figure 3). Furthermore, there were no differences among 
groups in Iba-1 immunoreactivity in the lumbar spinal dorsal horn (Figure 4) suggesting that 
microglial activation does not contribute to diet-induced mechanical hyperalgesia in high-fat fed 
nondiabetic or diabetic mice. 
 
TNF-α levels in Serum and Peripheral Tissues 
 Because TNF-α is often increased in inflammatory pain models [248, 249] and is 
typically elevated in the serum and periphery in obese humans and rodents [250-254] ,we 
assessed TNF-α in the serum and peripheral tissues. In contrast to our prediction, TNF-α was 
reduced in NdHF and DbStd groups compared to the NdStd group (Figure 5A). However, it 
should be noted that there were only 2 mice in the DbStd group for the serum measurement. The 
n was especially small for this group because serum volumes were too low in several samples 
due to use in previous experiments. Thus, results should be interpreted carefully. In addition,  
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Figure 3: Mechanical hyperalgesia is not accompanied by altered cytokine or chemokine 
expression in the lumbar spinal cord. 
Cytokines and chemokines were measured by multiplex ELISA at 8 weeks post-STZ and after 8 
weeks of the high-fat diet.   Data are presented as means ± SEM (n = 7-10 mice per group). No 
significant differences among groups. 
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Figure 4: Microglial activation in the lumbar spinal dorsal horn is not impacted by 
diabetes or a high-fat diet.  
Microglial activation was quantified using immunohistochemistry for Iba-1 in the lumbar dorsal 
horn of the spinal cord. Tissues were harvested at 8 weeks post-STZ and after 8 weeks of high-
fat feeding.  A-D) Representative images showing sections of the lumbar dorsal horn used to 
quantify microglial activation. A) Nondiabetic standard diet. B) Nondiabetic high-fat diet. C) 
Diabetic standard diet. D) Diabetic high-fat diet. Scale bar = 100µm. E) Quantification of Iba-1 
immunoreactivity within the lumbar dorsal horn.  Data are presented as means ± SEM. (n = 5-7 
mice per group). No significant differences among groups. 
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Figure 5: TNF-α expression in serum and peripheral tissues.  
TNF-α levels were measured by ELISA at 8 weeks post-STZ and after 8 weeks of high-fat 
feeding. A) Serum (n = 2-8 mice per group). B) Sciatic nerve (n = 10-13 mice per group). C) 
Hindpaw plantar skin  (n = 3-9 mice per group). D) Gastrocnemius (n = 10-13 mice per group).      
Data are presented as means ± SEM. *P < 0.05. 
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there were no significant differences among groups in TNF-α levels within sciatic nerve (Figure 
5B), the hindpaw plantar skin (Figure 5C).   
 
5. Discussion 
 Inflammation is considered to be a major factor underlying the pathogenesis of type 2 
diabetes, and has also been proposed as a major factor in the development of diabetic neuropathy 
in animal models [102, 255]. In addition, human patients with diabetic neuropathy have 
increased serum cytokine levels compared to healthy control subjects [93, 256]. Furthermore, 
serum pro-inflammatory cytokine levels are higher in patients with painful neuropathy compared 
to patients with painless neuropathy [93, 95, 256]. Purwata et al. also specifically reported higher 
serum TNF-α levels in patients with severe pain versus mild pain [93]. Consistent with these 
clinical findings, TNF-α levels in the lumbar dorsal spinal cord of diabetic rats were negatively 
correlated with paw withdrawal threshold suggesting elevated TNF-α levels may contribute to 
mechanical hypersensitivity [257]. 
 High-fat-fed nondiabetic rodents display signs of diabetic neuropathy including nerve 
conduction velocity deficits, altered sensorimotor behavior, and reduced intraepidermal nerve 
fiber density [5, 23, 30, 258, 259]. High-fat-fed mice exhibit mechanical hyperalgesia, indicative 
of increased nociception, characteristic of a painful phenotype of diabetic neuropathy. Although 
high-fat diet induced mechanical hyperalgesia has been documented in the literature [23, 30], the 
mechanism underlying this diet-induced neuropathy phenotype is unknown. The aim of this 
study was to investigate the role of inflammation as a potential mechanism underlying high-fat 
diet induced mechanical hyperalgesia. Here, we report high-fat diet induced mechanical 
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hyperalgesia is not accompanied by spinal inflammation or microglial activation in nondiabetic 
or diabetic mice after 8 weeks of diabetes and/or high-fat feeding. 
 
High-Fat Diet Induced Mechanical Hyperalgesia is Not Accompanied by Inflammation 
 Contrary to our hypothesis, we did not observe changes in chemokines or cytokines in the 
lumbar spinal cord of diabetic or high-fat-fed mice. These results were surprising and are in 
contrast to the large body of work documenting the association of a pro-inflammatory cytokine 
profile with painful diabetic neuropathy (reviewed in [88]) and reports of high-fat diet induced 
inflammation. However, only one of the studies reviewed by Wilson and colleagues [88] 
examined cytokine levels in the spinal cord and this study was done in rats after 4 weeks of 
diabetes [257]. It is plausible that our results were different because cytokines were measured 
later in the course of diabetes (8 weeks post-STZ) and were assessed in mice rather than rats.  
 In the current study, we also examined TNF-α levels in serum and several peripheral 
tissues because TNF-α is a pro-inflammatory cytokine that is commonly implicated in 
inflammatory pain [248, 249], diabetic neuropathy [89, 93, 99, 256] , and obesity induced 
inflammation [250-254]. In contrast with reports documenting increased TNF-α levels in 
painful neuropathy in human patients and STZ-induced diabetic rodents [89, 93, 99, 256]  TNF-
α levels in the serum, sciatic nerve, gastrocnemius, or hindpaw plantar skin were not 
significantly increased in NdHF, DbStd, or DbHF. In fact, serum TNF-α levels were reduced in 
NdHF and DbStd compared to nondiabetic mice fed the standard diet. It should be noted that 
serum from only 2 mice in the DbStd group were assessed for TNF-α, thus changes in serum 
TNF-α in the DbStd group should be interpreted with caution. Interestingly, in the sciatic nerve, 
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the P-value was 0.06 for NdStd vs. NdHF, indicating a trend toward increased TNF-α in the 
sciatic nerve of nondiabetic mice that consumed a high-fat diet. However, there was not a trend 
toward increased sciatic TNF-α in DbHF, the other group that exhibited mechanical 
hyperalgesia, suggesting that elevated sciatic TNF-α is not driving the painful phenotype in both 
nondiabetic and diabetic mice.  
 In the current study, STZ-diabetic mice fed the standard diet study exhibited insensate 
neuropathy, which is consistent with previous studies in this mouse strain [181-184].  Many of 
the reports of increased TNF-α levels are in STZ-diabetic rodents that display a painful 
neuropathy phenotype. Therefore, we expected to see inflammatory changes in the high-fat-fed 
nondiabetic and diabetic mice in conjunction with mechanical hyperalgesia and did not expect 
to see inflammatory changes the diabetic mice fed the standard diet.  However, in support of our 
results, Saleh and colleagues recently reported decreased TNF-α levels in DRG from STZ-
diabetic rats and posited that reduced TNF-α expression in the DRG may contribute to impaired 
nerve regeneration and collateral sprouting in type 1 diabetes [108]. Again, differences in our 
results compared to previous reports may be attributed to different time points at which 
experiments were performed.  
 It is noteworthy to mention that none of the previous studies have examined cytokine 
levels in STZ-induced diabetic mice fed a high-fat diet, which we report here. Analysis of 
additional cytokines and chemokines in the serum and peripheral tissues would better 
characterize the inflammatory or non-inflammatory state. Since adipose inflammation has been 
implicated as a major contributor to inflammation associated with obesity or a high-fat diet [78, 
124, 260-263], future studies will specifically assess inflammatory factors in adipose tissue. 
Furthermore, the DRG should be included in future inflammatory profiling because the DRG 
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could be a key site where inflammation might induce mechanical hyperalgesia in the hindpaws. 
Moreover, studies designed to assess central and peripheral nervous system inflammation at the 
onset of hyperalgesia may reveal early inflammatory changes that are ameliorated by 
compensatory mechanisms after several weeks.  
 
High-Fat Diet Induced Mechanical Hyperalgesia is Not Accompanied by Microglial Activation 
 In models of inflammatory pain, microglial activation often is viewed to go hand in hand 
with spinal and peripheral inflammation [239, 264-267]. Microglia can be a source of pro-
inflammatory cytokines and have been deemed necessary to produce pathological pain in 
laboratory animals [243-245]. Spinal glial activation has been reported in rodent models of 
diabetic neuropathy that display mechanical allodynia but these studies are few and only one 
study evaluated mice  [246, 268, 269]. In the current study, there were no differences in 
microglial activation among groups, indicating that diabetes nor the high fat diet affected 
microglial activation in the lumbar spinal dorsal horn.  In support of this, Gardiner and 
colleagues have recently reported that microglial activation is not increased in the lumbar dorsal 
spinal horn of STZ-induced diabetic C57Bl/6 mice (unpublished data). In addition, there is 
some controversy surrounding measurement of microglial activation. Activated microglia can 
hypertrophy, increase expression of activation markers, undergo morphological changes, an/or 
increase in number [248, 270, 271]. However, microglial activation has also been described as 
increased microglial number with retraction of processes [272]. In fact, Jonas and colleagues 
recently reported that microglial undergo several morphological stages of activation, and were 
the first to describe these stages in detail [272].  Thus, the method used to quantify Iba-1 
immunoreactivity should be chosen carefully. We chose to use percent threshold area to 
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quantify microglial activation because this method is commonly used in injury models of 
neuropathic pain [247, 248]. Although Gardiner and colleagues used a slightly different method 
and counted microglia on a grid, our results were still similar suggesting that microglial 
activation is not increased in STZ-induced diabetic mice fed a high-fat diet. To our knowledge, 
ours is the first study to examine microglial activation in high-fat-fed nondiabetic or diabetic 
mice. 
 In conclusion, a high-fat diet induced mechanical hyperalgesia was not accompanied by 
increased spinal inflammation, microglial activation, or increased TNF-α levels in the periphery 
suggesting inflammation is not driving mechanical hyperalgesia in this model. Importantly, this 
was the first time that cytokines, chemokines, and microglial activation have been assessed in 
this novel combination STZ-induced diabetes/high-fat diet model of diabetic neuropathy. 
Although there were not significant inflammatory changes at this time point, it is plausible to 
suggest that inflammation occurred earlier in the study near the initiation of behavioral changes 
and by the time we examined tissues at week 8, these changes were already downregulated by 
compensatory mechanisms. Future studies will investigate inflammatory mediators in additional 
tissues including the DRG and adipose at the initiation of behavioral changes in nociception.  
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CHAPTER 5 
The Effects of Exercise on Insulin Signaling in Mice Fed a High-Fat Diet 
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1. Abstract 
 Insulin resistance has been thoroughly characterized in insulin-dependent tissues 
including muscle, fat, and liver in diabetic animals and humans. Emerging evidence 
demonstrates that insulin resistance occurs in neurons and neuronal insulin resistance has been 
proposed as a novel etiological factor that contributes to neurodegeneration and dysfunction that 
occurs in diabetic neuropathy. The purpose of this study was to determine if  high-fat-fed 
nondiabetic mice that display signs of painful neuropathy also exhibit neuronal insulin 
resistance. In addition, we tested the effects of exercise on insulin signaling and mechanical 
sensitivity in nondiabetic mice that were fed a high-fat diet. Adult C57Bl/6 mice consumed a  
standard or high-fat diet for four weeks. In addition, half of the high-fat-fed nondiabetic mice 
had ad libitum access to a running wheel for the entire duration of the four-week study.  After 
stimulation via intra-peritoneal insulin injection, insulin signaling in the lumbar DRG, sciatic 
nerve, and gastrocnemius was evaluated using Western blots to quantify Akt activation. 
Although mechanical sensitivity was not significantly different among groups over the course of 
the four-week study in this cohort of animals, we have previously observed mechanical 
hyperalgesia in this mouse strain and these behavioral changes begin to appear after 4 weeks of 
high-fat feeding. Exercise prevented  increased body weight, glucose and insulin levels, and 
HOMA-IR in nondiabetic mice fed a high-fat diet. Akt activation in the DRG and sciatic nerve 
was not significantly affected by the high-fat diet or exercise. In contrast, Akt activation was 
significantly blunted in the gastrocnemius of high-fat-fed sedentary mice and this impairment 
was partially restored by exercise. In conclusion, exercise is an effective intervention to combat 
the deleterious effects of a high-fat diet on insulin resistance and other metabolic variables. 
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Together, these data demonstrate the potent ability of exercise to ameliorate or diminish 
metabolic derangements induced by a high-fat diet.  
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2. Introduction 
 Insulin resistance is a hallmark feature of type 2 diabetes and has recently been reported 
to occur in type 1 diabetes [110-113]. Insulin resistance in the setting of diabetes has been well 
characterized in insulin-dependent tissues including muscle, fat, and liver [114-116], but has not 
been thoroughly studied in the peripheral nervous system. Neurons respond to insulin, but 
neuronal glucose uptake occurs in an insulin-independent manner that is different than glucose 
uptake in muscle, fat and liver [117, 118]. Although neurons do not require insulin for glucose 
uptake, insulin is an important neurotrophic factor that neurons rely on for growth [121, 122], 
regeneration [123-125], and maintenance of mitochondrial function [21, 66]. Blunted insulin 
signaling and diminished insulin-stimulated neurite outgrowth has been reported in the DRG 
from diabetic rodents [117, 132]. Therefore, recently, impaired neuronal insulin signaling has 
been proposed as an etiological factor involved in neuronal damage and neurodegeneration that 
occurs in diabetic neuropathy [109, 132]. 
 Insulin resistance in peripheral tissues is consequence of a high-fat diet in rodents and 
humans [273-278]. There are also several studies reporting the beneficial effects of exercise on 
insulin sensitivity in insulin-dependent tissues in diabetic patients and high-fat-fed animals . 
[150, 155, 156]. However, to our knowledge, no one has investigated the effects of a high-fat 
diet or exercise on insulin signaling in the peripheral nervous system. We have previously 
discovered that a high-fat diet induces signs of painful neuropathy in sedentary mice [279].  
Thus, further study on peripheral nervous system insulin signaling in high-fat models of diabetic 
neuropathy is warranted.  Therefore, the aim of this study was to determine whether blunted 
peripheral nervous system insulin signaling occurs in conjunction with the behavioral changes 
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that occur in this high-fat model of diabetic neuropathy. In addition, we investigated the effects 
of exercise on sensorimotor behavior and insulin signaling in high-fat-fed mice.  
 
3. Experimental Procedures 
Animals, Diet, and Voluntary Exercise 
Seven week-old male C57Bl/6 mice were purchased from Charles River (Wilmington, 
MA). Mice were housed two mice per cage under pathogen free conditions, and placed on a 
12:12h light/dark cycle in the research support facility at the University of Kansas Medical 
Center. All animals had ad libitum access to food and water and were fed a standard diet (8604; 
Harlan Teklad, Madison Wisconsin; 14% kcals from fat, 32% protein, and 54% carbohydrate) or 
high-fat diet (07011; Harlan Teklad; 54% kcals from fat comprised of lard and corn oil, 21% 
protein, and 24% carbohydrate) for 4 weeks. Half of animals on the high-fat diet were randomly 
assigned to the exercise group. Exercised mice were housed individually in a cage with ad 
libitum access to a running wheel for the duration of the 4-week study. Mice in both the 
sedentary and exercise groups began the high-fat diet (and the exercise group was placed in the 
exercise wheel cages) immediately following baseline behavioral testing. Each wheel revolution 
was recorded in thirty-minute intervals with the Vital View Data Acquisition System (Mini 
Mitter, Bend, OR) throughout the duration of the study. All protocols and procedures were 
approved by the University of Kansas Medical Center Animal Use and Care Committee. 
Treatment groups are abbreviated throughout as follows: standard diet sedentary (SS); high-fat 
diet sedentary (HS); high-fat exercised (HE). 
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Behavioral Testing for Mechanical Sensitivity 
 Behavioral testing was performed as described in the previous chapters. In this specific 
study, behavioral testing was performed at baseline and every week thereafter for four weeks. 
Mice were placed on an elevated wire mesh screen (55 cm above table), enclosed individually in 
clear plastic cages, and mechanical sensitivity was assessed using a 1.4 g Semmes Weinstein von 
Frey monofilament (Stoelting, Wood Dale, IL) that was applied 6 times to each hind paw 
footpad. A mean percent withdrawal from a total of 12 applications was calculated per mouse 
and used to calculate group means.  
 
Glucose, Insulin, and HOMA-IR 
 Following a three hour fast, blood was collected at baseline and at the end of the 4-week 
study immediately before insulin stimulation. Samples were assayed for glucose using glucose 
diagnostic reagents (Sigma, St. Louis, MO). For insulin measurements, blood was collected into 
a heparinized microcapillary tube, then pipetted into an Eppendorf tube, and centrifuged for 15 
minutes at 3,000 x g. Plasma was removed and frozen at -80 oC. Insulin levels were measured 
using ELISA (mouse insulin Elisa, Alpco, Salem, NH). Fasting insulin and fasting glucose levels 
were used to calculate the homeostatic model assessment of insulin resistance (HOMA-IR), a 
measure of insulin resistance.  The following equation was used to calculate HOMA-IR values: 
Blood (Glucose (mg/dl) X (Serum Insulin (uU/mL)/405 [280]. 
Insulin Stimulation 
 Following a three hour fast, sterile PBS (vehicle) or 10 U/kg Humulin R insulin was 
administered to mice from the SS, HS, and HE groups. Humulin R insulin was diluted to 0.001 
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U/µL in sterile PBS and 10 µl/g was injected via a single intra-peritoneal injection. Thirty 
minutes after insulin injection, mice were anesthetized with isofluorane and decapitated. Blood 
was collected from the decapitation pool for post-insulin stimulation glucose quantification. 
 
Western Blots for Akt Activation 
After the 30 minute insulin stimulation period, mice were killed as described above and 
the DRG, sciatic nerve, and gastrocnemius were harvested, snap frozen in liquid nitrogen, and 
stored at -80°C. Tissues were lysed with cell lysis buffer (137 mM NaCl, 20 mM Tris [pH 8.0], 
1% NP40, and 10% glycerol) containing protease inhibitors (0.5 mm sodium vanadate, 1 µg/ml 
leupeptin, 10 µg/ml aprotinin, and 1 mM PMSF) and protein was extracted while tissue lysates 
were kept on ice for 1 hour and vortexed every 10 minutes. Samples were then centrifuged at 
10,000 g for 10 minutes at 40 C and the protein concentration of the supernatant was measured 
with a Bradford assay (Bio-Rad, Hercules, CA).  
Samples were prepared to achieve equivalent protein concentrations then boiled at 95-
100 0C with Lane Marker Reducing Sample Buffer (Thermo Scientific, Waltham, MA) for 3 
minutes. Samples containing 30 µg of protein were separated by electrophoresis (35 mA/gel, 
0.75 hr, 40 C) on 4-15% gradient tris-glycine polyacrylamide gels (Bio-Rad) and transferred onto 
nitrocellulose membrane (400 mA, 1.5 hr, 40C).  Nitrocellulose membranes were blocked for 1 
hour at room temperature in blocking solution (5% non-fat powdered milk and 0.05% Tween-20 
in 0.1 M phosphate buffered saline [PBST, pH 7.4]), followed by overnight incubation (40C) in 
primary antibody diluted in blocking solution (1% non-fat powdered milk and 0.05% 0.1 M PBS 
( pH 7.4).  
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Membranes were probed using following antibodies: total Akt (Cell Signaling), 
phospho(Ser473)Akt (Cell Signaling), β-actin (Millipore). Membranes were washed in PBST, 
and then incubated in either anti-mouse or anti-rabbit horse radish peroxidase conjugate (Santa 
Cruz) for 1 hour at room temperature. Bands were visualized by enhanced chemiluminescence 
(ECL) using Supersignal West (Femto or Pico) Substrate (Pierce, Rockford, IL) and detected on 
X-ray film. Bands were quantified via densitometry using NIH Image J software.  
 
Statistics  
 Data were analyzed using a two-factor analysis of variance (ANOVA) or repeated 
measures ANOVA with Fisher’s test of least square difference post-hoc comparisons. Statistical 
significance was set at P < 0.05. 
 
4. Results and Figures 
Body Weight, Glucose, Insulin 
 Sedentary mice fed the high-fat diet had increased body weight (Figure 1A), glucose and 
insulin levels (Figure 2A-B), and HOMA-IR (Figure 2C) compared to sedentary mice on the 
standard diet. Although elevated glucose and hyperinsulinemia in high-fat sedentary mice 
suggested these mice were in a pre-diabetic state, glucose levels were not high enough to be 
classified as overt diabetes (Figure 2A-B). Body weight (Figure 1), glucose, insulin, and HOMA-
IR (Figure 2A-C) were not different from standard diet sedentary mice in the high-fat exercise 
group, thus voluntary running wheel exercise prevented deleterious changes in all of these 
metabolic variables. 
135 
 
Figure 1: Exercise prevents excess weight gain in mice fed a high-fat diet. 
Body weight was significantly higher in sedentary mice after 4 weeks of high-fat feeding 
compared to sedentary standard diet mice and high-fat exercised mice. Data are presented as 
means ± SEM (n = 19 – 21 mice per group).  ###P < 0.001 for  SS vs. HS and ***P < 0.001 for 
HS vs. HE. 
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Figure 2: Exercise prevents metabolic defects in high-fat fed mice. 
A) Blood glucose following a 3-hour fast. #P < 0.05 for  SS vs. HS and **P < 0.01 for HS vs. 
HE. B) Serum insulin after 3-hour fast. Blood was collected after 4 weeks of high-fat feeding 
and/or exercise. *P < 0.05. C) Homeostatic model of insulin resistance (a measure of insulin 
resistance) after 4 weeks of high-fat feeding and/or exercise. *P < 0.05. Data are presented as 
means ± SEM (n = 18-20 mice per group).  
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Exercise Distance and Timing 
 High-fat-fed mice had ad libitum access to a running wheel in their individual cages 24 
hours per day, 7 days per week. However, due to their nocturnal nature, mice perform the bulk of 
their running during the dark portion of the 12 hr light/dark cycle that occurs from 6 pm to 6 am 
(Figure 3A). Daily running distance is calculated by multiplying the number of wheel turns by 
the diameter of the wheel and according to these calculations, on average, these mice ran 9.9 km 
per 24 hour day (Figure 3B). As illustrated in Figure 3B, running distance is similar to a bell 
curve over the course of the four weeks, with running distance increasing to peak at week 2 and 
tapering off by week 4.  
 
Mechanical Sensitivity 
 Behavioral responses to twelve repeated applications of a 1.4 g von Frey monofilament 
were calculated as percent paw withdrawal. Although there were no significant differences 
among groups in this cohort of animals (Figure 4), sedentary high-fat-fed mice develop 
mechanical hyperalgesia compared to standard diet sedentary mice [30] and we have 
documented this in numerous cohorts in our laboratory. However, mechanical hyperalgesia 
typically first appears after 4 weeks of high-fat feeding and is more well established after 8 
weeks of a high-fat diet. In some cohorts, increased mechanical sensitivity is statistically  
significant at week 4 while in other cohorts, mechanical sensitivity is not different from standard 
diet mice. This inconsistency is due to the fact that this time point is near the initiation of 
behavioral changes, on the cusp of when mechanical hypersensitivity develops. Because we 
wanted to characterize insulin sensitivity at the initiation of behavioral changes, we specifically  
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Figure 3: Mice consistently engage in voluntary exercise throughout the duration of the 4- 
week study and perform the majority of their running between the hours of 6 pm and 6 am. 
A) Twenty four hour exercise timeline in exercised mice fed a high-fat diet. B) Daily running 
distance in exercised mice fed a high-fat diet high. Data are presented as means ± SEM (n = 19).  
**P < 0.01 for week 2 vs. week 3.  ***P < 0.001 for week 1 vs. week 2. 
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Figure 4: The effects of a high-fat diet on mechanical sensitivity in sedentary and exercised 
mice.  
Mechanical sensitivity was assessed after 4 weeks of a high-fat diet and sedentary activity or 
exercise using 12 repeated applications of a 1.4 g von Frey monofilament. Data presented as 
means ± SEM (n = 10 – 12 mice per group). No significant differences.  
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chose to use 4 weeks of high-fat feeding. Exercise did not significantly alter mechanical 
sensitivity in high-fat-fed mice at these early time points in this short-term study (Figure 4).   
 
Response to Insulin 
 In order to ensure the efficacy of the 30-minute insulin stimulation, we measured blood 
glucose levels before and after 30-minute insulin stimulation. Although there were no 
statistically significant differences among groups, glucose was reduced by 53% in high-fat-fed 
exercised mice compared to a 39% and 41% reduction in glucose after insulin stimulation 
compared to sedentary diet sedentary and high-fat-fed sedentary mice (Figure 5). This data 
points to increased insulin sensitivity in exercised mice compared to sedentary mice. 
 
Akt Activation 
 Insulin signaling was evaluated after insulin stimulation by quantifying Akt activation 
(pAkt/total Akt) in peripheral tissues. In SS, HS, and HE, insulin injection elicited a significant 
increase in Akt activation in the DRG, sciatic nerve, and gastrocnemius compared to PBS 
injection in the corresponding group (Figure 6A-C). There were no significant differences among 
groups in pAkt/total Akt in the DRG (Figure 6A) or sciatic nerve (Figure 6B), indicating that the 
neither high-fat diet, nor exercise impacted insulin sensitivity in these tissues. In stark contrast,  
insulin stimulated Akt activation was significantly blunted in the gastrocnemius of high-fat-fed 
sedentary mice compared to standard diet sedentary mice (Figure 6C). Akt activation was 
significantly higher in the high-fat exercised mice compared to high-fat-fed sedentary mice, thus   
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Figure 5: The effects of insulin stimulation on glucose levels in sedentary and exercised 
mice fed a high-fat diet. 
Following a 3 hour fast, mice were administered a single intraperitoneal injection of sterile PBS 
or insulin (0.1 U/kg) 30 minutes before sacrifice. Blood was collected immediately before 
injection and then immediately after the 30 minute stimulation period upon sacrifice. Response 
to injection was reported as percent change in glucose level and calculated according to the 
following formula: ([post-injection glucose level – pre-injection glucose level] 
/ pre-injection glucose level) * 100. Data are presented as means ± SEM (n = 7-11 mice per each 
of 6 groups).  No significant differences. 
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Figure 6: Exercise improves blunted Akt activation in skeletal muscle of high-fat-fed mice. 
Tissues were harvested following insulin stimulation at the end of the 4-week study. Following a 
3 hour fast were administered a single intraperitoneal injection of sterile PBS or insulin (0.1 
U/kg) 30 minutes before sacrifice. In all cases except the high-fat exercise group in the sciatic 
nerve, insulin-stimulation significantly increased Akt activation compared to PBS. Proteins were 
measured by Western blot. Representative images and quantification of group means. Insulin-
stimulated Akt activation in the lumbar dorsal root ganglia (A), sciatic nerve (B), and 
gastrocnemius (C).  Phosphorylated (ser473) Akt band intensities were normalized to total Akt. 
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exercise effectively attenuated the deleterious effects of the high-fat diet on insulin signaling in 
muscle (Figure 6C). However, high-fat-fed exercised mice still had significantly lower Akt 
activation than sedentary standard mice, thus 4 weeks of exercise did not completely restore Akt 
activation to normal levels (Figure 6C). 
 
5. Discussion 
 Here, for the first time, we report the effects of a high-fat diet and exercise on insulin 
signaling in neural tissues. In addition, our data indicates the potent ability of exercise to modify 
negative metabolic changes associated with diabetes and neural complications in a pre-diabetic 
model of painful diabetic neuropathy. 
 High-fat feeding clearly had detrimental metabolic effects in sedentary mice. Consistent 
with previous reports in the literature, a high-fat diet induces pre-diabetes characterized by 
elevated glucose, hyperinsulinemia, and systemic insulin resistance (increased HOMA-IR) in 
sedentary mice [23, 41]. Importantly, in the current study, exercise powerfully prevented each of 
these high-fat diet induced metabolic derangements.  
 Although insulin resistance is a key feature of type 2 diabetes and has been well 
described in type 2 diabetes [116, 277, 281, 282] and documented in type 1 diabetes [112, 114], 
there are few studies investigating insulin resistance in the peripheral nervous system. Blunted 
insulin signaling in the DRG from diabetic animals has recently been reported in the literature 
[117, 132]. Moreover, neuronal insulin resistance has recently been suggested as a potential 
mechanism involved in the pathophysiology of diabetic neuropathy [109]. As we have recently 
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discovered that a high-fat diet induces mechanical hyperalgesia in mice, we were interested in 
whether neuronal insulin resistance accompanied these behavioral changes.   
 Experiments in this study quantified Akt activation after insulin stimulation, which is a 
common and accepted method used to evaluate insulin signaling and insulin resistance in the 
peripheral nervous system and other peripheral tissues. Although the high-fat diet did not 
significantly impair insulin signaling in the DRG or sciatic nerve in sedentary mice, the fold 
change in Akt activation between PBS and insulin was lower in high-fat-fed (2.4 in DRG, 9.5 in 
sciatic) compared to standard diet fed sedentary mice (2.7 in DRG, 14.8 in sciatic) in both of 
these tissues. In the sciatic nerve, the reduction in insulin signaling is likely not significant due to 
the high standard error in the standard diet sedentary group. These data suggest that a high-fat 
diet does not impair insulin signaling in neural tissues to the extent that it does in muscle, but it 
appears theses tissues are headed toward of insulin resistance and there are dietary effects. If the 
study had been carried out for 8 weeks, decreased insulin signaling would potentially be 
significant in the neural tissues. Despite subtle changes in Akt activation in the peripheral 
nervous system, the high-fat diet and exercise had potent effects on insulin signaling in muscle.  
In the gastrocnemius, impaired Akt activation was partially restored by exercise in high-fat-fed 
mice. The results in this study were consistent with previous reports that exercise improves high-
fat diet-induced insulin resistance in muscle [149, 283, 284]. Importantly, exercise training also 
improves muscle insulin resistance in type 2 diabetic patients [155]. Increased glucose uptake via 
enhanced insulin stimulated Glut4 translocation is a key mechanism responsible for exercise-
induced improvements in insulin sensitivity that has been documented in the literature [285, 
286]. However, this is the first time the effects of a high-fat diet on neuronal insulin signaling in 
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sedentary and exercised mice have been studied, thus potential mechanisms underlying neural 
insulin resistance have not been elucidated in this high-fat model. 
 Behavioral changes in mechanical sensitivity were not yet significant after four weeks of 
high-fat feeding in this cohort of animals. However, the initiation of mechanical hyperalgesia in 
high-fat-fed sedentary mice typically occurs somewhere near the 4-week time point and is well 
established after 8 weeks of a high-fat diet, thus these results were not surprising. We purposely 
chose to examine peripheral nervous system insulin sensitivity after short-term high-fat feeding 
to determine if insulin resistance occurs near the onset of behavioral changes. Although there 
were no statistically significant changes in mechanical sensitivity, percent paw withdrawal was 
65% in standard diet sedentary mice while it was 70% in high-fat-fed sedentary mice at week 4, 
suggesting that the HS group is headed toward mechanical hypersensitivity. In addition, insulin 
signaling was not signficantly impaired in the DRG or sciatic, but at the sciatic nerve appears to 
be headed toward insulin resistance. The lack of significant changes in insulin signaling and 
mechanical sensitivity coupled with the appearance that these parameters are moving in the 
direction of neural insulin resistance and mechanical hyperalgesia, suggest these changes may 
track together in high-fat-fed sedentary mice. If mechanical hyperalgesia developed in 
conjunction with neural insulin resistance, it is plausible to suggest that neural insulin resistance 
may play a role in high-fat diet induced mechanical hyperalgesia.  
 Previous studies in our laboratory (Groover, unpublished data) indicate exercise reverses 
high-fat diet induced mechanical hyperalgesia, but this does not occur until after 8-12 weeks of 
exercise in high-fat-fed mice. Thus, it was not surprising that exercise did not significantly 
impact mechanical sensitivity at these early time points in this short-term study.   
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 In conclusion, voluntary running wheel exercise was effective at preventing detrimental 
changes in body weight, glucose, insulin, and insulin signaling in high-fat-fed mice. Although 
peripheral nervous system insulin signaling was not significantly altered by a high-fat diet or 
exercise, exercise attenuated insulin resistance in the muscle of high-fat-fed mice. Results from 
this study emphasize the importance of exercise in preventing or reversing metabolic 
derangements and neural complications associated with pre-diabetes. 
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CHAPTER 6 
Conclusions 
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Diabetic neuropathy is the most common and debilitating complication of diabetes. 
Although the majority of diabetic patients will develop some form of peripheral neuropathy, 30-
40% of diabetic patients do not develop neuropathic symptoms. It is unclear why some patients 
escape sensory complications.  In addition, the reason why some patients suffer from painful 
symptoms while others present with painless symptoms remains elusive. There are also 
increasing reports of nondiabetic patients with pre-diabetes and nondiabetic individuals with 
normal glucose levels who develop neuropathy. It is clear that peripheral sensory neurons are 
damaged via several metabolic insults that are primarily due to hyperglycemia. However, the 
dichotomous presentation of neuropathic symptoms, the fact that not all diabetic patients develop 
neuropathy, and the prevalence of neuropathy among pre-diabetic patients points to additional 
etiological factors besides hyperglycemia.  An evolving body of clinical evidence has established 
dyslipidemia as an independent risk factor for the development of neuropathy. Because the 
majority of dyslipidemia cases in adult humans can be attributed to excess energy and fat intake, 
diet may play an important role in the development of diabetic neuropathy. 
The overall purpose of this study was to better understand the role of diet and 
dyslipidemia on the development and progression of diabetic neuropathy and identify potential 
mechanisms underlying the pathogenesis of high-fat diet induced neuropathy. Studies in this 
dissertation evaluated the effects of a high-fat diet on parameters used to characterize neuropathy 
including sensorimotor behavior, nerve conduction velocity, and epidermal innervation in 
nondiabetic and diabetic mice. In addition, experiments were performed to assess mitochondrial 
dysfunction, inflammation, and insulin sensitivity as potential pathological mechanisms 
responsible for the effects of high-fat feeding on sensory changes. 
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Chapter 2: Phenotypic Changes in -Fat Diet in Diabetic Neuropathy Induced by a High 
Diabetic C57Bl/6 Mice 
 Although clinical evidence and rodent studies suggest that dyslipidemia and/or diet plays 
an important role in the development and progression of diabetic neuropathy, the effects of a 
high-fat diet in conjunction with type 1 diabetes has not been studied. Here, for the first time, we 
report the effects of a high-fat diet and dyslipidemia on neuropathic symptoms in nondiabetic 
and STZ-induced type 1 diabetic mice.  
 The findings from this study were both surprising and groundbreaking for the diabetic 
neuropathy field. Interestingly, STZ-induced diabetic C57Bl/6 mice fed a high-fat diet developed 
dyslipidemia and a painful neuropathy (mechanical hyperalgesia) instead of the insensate 
neuropathy (mechanical insensitivity) that normally develops in this mouse strain. This finding is 
particularly important because it suggests that diet may modulate diabetic neuropathy phenotype. 
Nondiabetic mice fed the high-fat diet also developed dyslipidemia and painful neuropathy. In 
terms of mechanical sensitivity, the effect of the high-fat diet appears to overpower the effect of 
diabetes in this mouse strain. STZ-diabetic mice first develop hyperalgesia, rather than loss of 
sensation. Additionally, STZ-diabetic mice developed mechanical hyperalgesia with a similar 
time course and severity as the nondiabetic mice. These data suggest that influence of diet or 
dyslipidemia is potent, and perhaps over the course of several years, diet may have a profound 
influence on neuropathic symptoms in nondiabetic or diabetic humans. Furthermore, these 
results provide new insight to suggest diet may play a role in determining the neuropathy 
phenotype in human diabetic patients. 
 It is noteworthy to mention that although high-fat-fed nondiabetic and diabetic mice were 
both dyslipidemic, the NdHF group had elevated total cholesterol and LDL-C while the DbHF 
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group had elevated triglycerides. Although the majority of large clinical population studies 
cluster derangements in one or many lipid variables together as dyslipidemia [33, 287, 288], one 
mutlti-center trial specifically demonstrated that elevated triglycerides, but not elevated total 
cholesterol, was correlated with loss of sural myelinated nerve fiber density in diabetic patients 
with neuropathy [287]. Thus, there is very little evidence to base conclusions on which lipid 
variables are more likely to affect neuropathy development and phenotype.   
 Since high-fat diets induce weight gain in humans and rodents, it could be argued that 
increased body weight or body fat rather than lipid status is driving the effects of high-fat diet 
induced neuropathy in the current study. However, high-fat-fed diabetic mice weighed less than 
both the nondiabetic mice fed the standard diet and diabetic mice fed the standard diet, 
suggesting that body weight is not the driving factor behind high-fat diet induced mechanical 
hyperalgesia. In support of our findings, Wiggin and colleagues demonstrated elevated 
triglycerides, but not BMI, were correlated with detrimental changes in peripheral sensory nerve 
fibers [287]. 
 In the current study, both diabetic groups exhibited thermal hypoalgesia but these sensory 
deficits were not exacerbated by the high-fat diet. It is not uncommon to observe opposite 
changes in mechanical and thermal sensory behavior in high-fat-fed nondiabetic rodents 
Consistent with our results, previous studies of high-fat-fed rodents report mechanical 
hyperalgesia and thermal hypoalgesia [5, 23, 41]. It has been proposed that the opposing 
mechanical and thermal behavioral changes in high-fat-fed rodents may be attributed to severe 
large myelinated fiber loss and morphological changes in conjunction with insignificant changes 
in small myelinated and unmyelinated fibers [41]. In the current study, sensory and motor nerve 
conduction velocity deficits were only present in diabetic mice that consumed the high-fat diet 
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compared to high-fat-fed nondiabetic mice. Thus, diabetes alone did not significantly impair 
nerve conduction velocity. These results are in contrast to some previous studies that report 
diabetes-induced deficits in sensory and motor nerve conduction velocities [5, 192, 289, 290]. 
However, there were only 3 animals in the DbStd group because several animals did develop 
diabetes after STZ-injection. It is also plausible to suggest that slowed sensory and motor nerve 
conduction velocities in the DbHF group compared to NdHF are in part due to increased sensory 
and motor nerve conduction velocities in nondiabetic mice fed a high-fat diet. We expect that 
high-fat feeding in growing nondiabetic mice may enhance myelination in large nerve fibers, and 
consequently result in the significant increases in sensory and motor nerve conduction velocities 
observed here. 
 Finally, nitrotyrosine, a marker of oxidative stress, was quantified in the DRG using 
immunohistochemistry. Surprisingly, the high-fat diet did not increase oxidative stress in high-
fat-fed nondiabetic or diabetic mice. In contrast, nitrotyrosine expression was increased in 
medium sized neurons in diabetic mice on the standard diet. These negative results weaken the 
hypothesis that lipid induced neuronal injury is due to increased oxidative stress via a LOX-1 
dependent mechanism.      
It would be interesting to investigate the effects of lipid lowering therapies such as statins 
to determine if dyslipidemia mediates the high-fat diet induced effects on sensorimotor behavior. 
Interestingly, data from NHANES 1999-2004 indicated statin use was associated with increased 
incidence of peripheral neuropathy in United States adults over the age of forty [291]. An 
additional future direction for this work would include investigating the effectiveness of omega-
3- fatty acid supplementation to prevent or reverse high-fat diet induced neuropathy.  Positive 
outcomes from future studies could lead to dietary modifications and/or increased use of 
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treatments that improve dyslipidemia (i.e. omega 3 fatty acid supplementation, statins, or 
exercise) as therapeutic interventions for patients with painful diabetic neuropathy. 
 
Chapter 3: Mitochondrial Function in Diabetic Neuropathy 
 Due to heavy reliance on mitochondrial energy production, neurons are especially 
sensitive to disruptions in mitochondrial dysfunction. Diabetes-induced hyperglycemia is 
associated with and may cause mitochondrial dysfunction in rodent models of diabetic 
neuropathy [63, 64, 66, 224, 292]. Consequently, mitochondrial dysfunction has been proposed 
as a key mechanism that contributes to neuronal dysfunction and damage in diabetic neuropathy 
[22, 224, 292]. In addition, previous reports suggest high-fat diet induced dyslipidemia leads to 
oxidative stress that can damage mitochondria [5].  We hypothesized that a high-fat diet in 
conjunction with STZ-induced type 1 diabetes would exacerbate mitochondrial dysfunction. In 
addition, we suspected neuronal mitochondrial dysfunction might be responsible for the robust 
behavioral phenotype associated with high-fat feeding. Here, we performed experiments to 
assess mitochondrial function in the lumbar DRG of nondiabetic and STZ-diabetic mice fed a 
standard or high-fat diet. The methodology utilized in this study was particularly novel. All 
previous studies that examined mitochondrial function in DRG in rodent models of diabetic 
neuropathy performed the mitochondrial respiration experiments using primary cultured DRG. 
This was the first time mitochondrial respiration has been quantified in whole, undisrupted DRG 
and their peripheral axonal processes. Furthermore, we used a novel high-fat/STZ-induced type 1 
diabetic mouse model of diabetic neuropathy. This was the first time mitochondrial function has 
been assessed in this unique diabetic neuropathy model. 
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 Results from this study indicated basal mitochondrial respiration was reduced while 
mitochondrial proteins Complex III subunit Core-2 and VDAC were increased in diabetic mice 
fed the standard diet. These results were consistent with previous studies reporting impaired 
mitochondrial respiration in lumber DRG from diabetic mice fed a standard diet. Despite 
increases in two mitochondrial proteins in the DbStd group, diabetes did not significantly alter 
the expression of proteins indirectly or directly involved mitochondrial function and biogenesis 
(UCP2, PGC-1a, Sirt1, pAmpk, pAkt, or pmTor). Surprisingly, the high-fat diet did not 
significantly impact mitochondrial respiration or the mitochondrial proteome in nondiabetic or 
diabetic mice. Because high-fat feeding was not associated with significant changes in 
mitochondrial respiration or the mitochondrial proteome, it is unlikely that mitochondrial 
dysfunction is driving the robust behavioral phenotype observed in high-fat-fed nondiabetic or 
diabetic mice.  
 Reduced basal respiration in conjunction with increases in expression of oxidative 
phosphorylation subunit (Complex III subunit Core-2) and VDAC could point to compensatory 
mitochondrial biogenesis in the DbStd group compared NdStd. However, an alternative theory 
could potentially explain these results. As described in Chapter 3, diabetic mice fed the standard 
have increased β-hydroxybutyrate levels, indicative of ketosis. In diabetes or starvation, excess 
Acetyl coenzyme A ( CoA)  is produced from fatty acid oxidation and is subsequently converted 
to acetoacetate and β-hydroxybutyrate in the liver. These ketones are released in the blood and 
transported to peripheral tissues where they can be used as alternate fuel sources rather than 
glucose. β-hydroxybutyrate can be converted to acetoacetate or utilized directly as an energy 
source. Acetoacetate is metabolized to produce two acetyl CoA that can enter the citric acid 
cycle.  
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 In order to breakdown acetoacetate to acetyl CoA, succinyl CoA is required in the first 
step of the reaction. In the citric acid cycle, succinyl CoA is converted to succinate. Next, 
succinate is converted to fumarate and FADH2 is produced. When an animal is in ketosis, 
succinyl-CoA is used to breakdown excess acetoacetate, resulting in excess succinate production. 
Consequently, additional succinate is available for the conversion to fumarate in the citric acid 
cycle and the result is increased FADH2 [293]. Therefore, increased acetoacetate breakdown can 
result in increased FADH2 production in the citric acid cycle [218].  
 Since Complex II of the electron transport chain relies solely on FADH2 as an electron 
donor, increased availability of FADH2 can result in increased electron flux through Complex II 
[218]. Consequently, the downstream components of the electron transport chain participate in a 
reduced proportion of the electron transport. Complex III is directly downstream of complex II 
thus increasing electron transport through complex II might reduce electron transport at complex 
III, thus stimulating an increase in Complex III subunits as observed in the diabetic mice fed the 
standard diet. The fact that the mice in DbHF group were also in ketosis but mitochondrial 
respiration and expression of mitochondrial oxidation phosphorylation proteins were not 
different from nondiabetic mice could weaken the “increased Complex II flux” argument. 
Although the reduction in basal mitochondrial respiration was not statistically significant in 
DbHF, it was 31% lower than NdStd while basal respiration in the DbStd group was similar and 
36% lower than DbStd and this difference was statistically significant. Although statistically 
insignificant, a minimal reduction in mitochondrial respiration may still be physiologically 
relevant. 
 In order to confirm or refute the “increased Complex II flux” theory proposed above, (to 
explain increased expression of Complex III Core-2 in DbStd), mitochondrial respiration 
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experiments should be performed in permeabilized DRGs or isolated mitochondria in order to 
evaluate complex specific respiration. It would be interesting and worthwhile to perform these 
experiments in freshly isolated (rather than cultured) DRG to further characterize the effect of 
diabetes and the high-fat diet on mitochondrial function in this novel model of diabetic 
neuropathy.  
 
Chapter 4: The Role of Inflammation in High-Fat Diet-Induced Hyperalgesia 
 Diabetes has been characterized as an inflammatory disease. Both type 1 and type 2 
diabetic patients exhibit a state of chronic low-grade inflammation [87] characterized by 
increased pro-inflammatory mediators in the circulation [294, 295], liver [296], adipose [77], 
immune cells [85, 100, 297], and/or muscle [298].  Hyperlipidemia has also been shown to cause 
chronic inflammation and contribute to the pathogenesis underlying type 2 diabetes [299]. 
Inflammation has recently been proposed as a mechanism contributing to the pathogenesis of 
diabetic neuropathy [74, 102, 255]  and has been specifically implicated in painful neuropathy 
[93, 256]. However, it is questionable whether inflammation is simply linked with diabetic 
neuropathy due to the role of inflammation in diabetes or if inflammation is a causative factor 
driving detrimental changes in the nervous system.   
 Obesity is also associated with a state of chronic low-grade inflammation [81, 82, 295, 
300] and high-fat feeding in rodents increases pro-inflammatory cytokine and chemokine 
expression in serum and peripheral tissues [124, 190, 301]. Because the high-fat-fed animals 
exhibited robust mechanical hyperalgesia and have increased body weight, we expected to 
observe spinal and/or peripheral inflammation in these animals. Here, we hypothesized that a 
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high-fat diet induced central and/or peripheral inflammation in conjunction with glial activation 
in the spinal cord, thus resulting in chronic mechanical hyperalgesia. Experiments performed in 
this study assessed spinal and peripheral inflammation along with microglial activation in 
nondiabetic and diabetic mice fed a standard or high-fat diet. This was the first time central and 
peripheral nervous system inflammation has been assessed in this novel high-fat/STZ-induced 
type 1 diabetic model of diabetic neuropathy. 
 In contrast with our hypothesis, diabetes nor the high-fat diet altered cytokines or 
chemokines associated with inflammation in the lumbar spinal cord. In addition, microglial 
activation in the lumber dorsal spinal horn was not different among groups. Furthermore, TNF-α 
expression was not significantly increased by diabetes or high-fat feeding in the serum, sciatic 
nerve, gastrocnemius, or footpad. Our findings were inconsistent with one previous study that 
reported increased lumbar spinal TNF-α and IL1-β in STZ-induced diabetic rats [257]. However, 
inflammation marker levels peaked at 4 weeks post-STZ. We did not assess spinal inflammation 
until 8 weeks post-STZ. It is plausible that compensatory mechanisms might return inflammatory 
markers to normal levels after the initial response, which would make inflammation undetectable 
at later stages of diabetes. The effects of a high-fat diet on inflammatory mediators in high-fat- 
fed STZ-induced diabetic mice have never been studied before, thus we have no previous results 
with which to compare our findings in this specific treatment group. 
 Although these results suggest spinal nor peripheral inflammation is driving the 
development of hyperalgesia after 8 weeks of high-fat feeding in nondiabetic and diabetic mice, 
further investigation is needed before completely ruling out inflammation as a potential 
mechanism underlying high-fat diet induced neuropathy. It is important to note that we have not 
yet examined inflammatory mediators in the DRG or adipose. The DRG could be a key site 
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where inflammation might induce mechanical hyperalgesia in the hindpaws. Moreover, it would 
be beneficial to evaluate inflammation at other key intervals along the time course of behavioral 
changes. Studies designed to assess central and peripheral nervous system inflammation just 
prior to and at the initiation of hyperalgesia may reveal early inflammatory changes that are 
ameliorated by compensatory mechanisms after several weeks. Although TNF-α is the molecule 
with most evidence to suggest a role for inflammatory cytokines in diabetic neuropathy, 
a more complete profile of inflammatory mediators should be examined in the serum and 
peripheral tissues. Finally, it would be interesting to determine if administration of an anti-
inflammatory agent prevents or reverses high-fat diet induced hyperalgesia. Perhaps 
inflammatory changes in high-fat-fed mice are physiologically relevant, but minimal enough to 
be undetectable with the current methodology.  
 
 
Chapter 5: The Effects of High-Fat Feeding and Exercise on Insulin Sensitivity 
 Emerging evidence indicates insulin resistance occurs in neurons as it does in insulin- 
dependent tissues in the setting of diabetes [117, 132]. Because insulin is a key neurotrophic 
factor that supports neurite outgrowth [121, 122], regeneration [123-125], and maintenance of 
mitochondrial function [21, 66],   impaired insulin signaling due to insulin resistance could lead 
to neuronal damage and degeneration.  Therefore, peripheral nervous system insulin resistance 
has recently been proposed as an etiological factor involved in the dying-back type neuronal 
degeneration that occurs in diabetic neuropathy [117].  
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 In this study, experiments were designed to determine if peripheral nervous system 
insulin resistance accompanied mechanical hyperalgesia in high-fat-fed nondiabetic mice, a 
model of pre-diabetes. In addition, we tested the effects of exercise on metabolic variables and 
insulin resistance in high-fat-fed mice. Importantly, voluntary running wheel exercise 
ameliorated the detrimental effects of the high-fat diet on body weight, circulating glucose and 
insulin levels, and HOMA-IR. In addition, impaired Akt activation in muscle was partially 
rescued by exercise in mice that consumed a high-fat diet. Although there were no statistically 
significant changes Akt activation in neural tissues, the pattern of the fold change from PBS to 
insulin-stimulated Akt activation was suggestive of a trend toward blunted insulin signaling in 
high-fat sedentary mice compared to standard diet sedentary mice. If the study was carried out a 
few weeks longer, perhaps significant peripheral nervous system insulin resistance would be 
present. 
 Previous reports from our laboratory and others indicate that nondiabetic rodents fed a 
high-fat diet develop mechanical hyperalgesia [23, 30, 41]. Studies in our laboratory have 
consistently indicated that mechanical hyperalgesia first begins to appear in C57Bl/6 mice after 4 
weeks of a high-fat diet ([30] and unpublished data). Thus, we specifically chose the 4-week 
time point in order to assess insulin sensitivity at the onset of behavioral changes. In the current 
study, high-fat-fed sedentary mice did not display statistically significant mechanical 
hyperalgesia after 4 weeks of high-fat feeding, but percent paw withdrawal threshold was 71% 
which was 13% higher than baseline. Similar to Akt activation, despite the lack of statistical 
significance, the behavior appears to be headed toward mechanical hyperalgesia in the high-fat 
sedentary group. Plus, we have consistently observed significant mechanical hyperalgesia  after 4 
weeks of high-fat feeding in multiple cohorts of mice.  
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 Considering the lack of statistically significant changes in insulin signaling and 
mechanical behavior, it would be interesting to assess these variables after 5, 6, 7, and 8 weeks 
of high-fat feeding to determine if behavioral changes occur near the same time as neural insulin 
resistance. Interestingly, insulin-stimulated Akt activation and neurite outgrowth is significantly 
decreased in DRG cultures from diabetic ob/ob mice (type 2 diabetes model) that exhibit 
mechanical hyperalgesia [132]. Although it has been purported that insulin resistance occurs in 
type 1 diabetes [302], to our knowledge, no one has examined insulin signaling in the peripheral 
nervous system in type 1 diabetic rodents. Moreover, to elucidate whether neural insulin 
resistance is more closely associated with a painful or painless phenotype of diabetic neuropathy, 
it would be beneficial to characterize insulin signaling in STZ-induced rodent model of insensate 
diabetic neuropathy. 
 
Impact on the Field 
 Altogether, this body of work was transformational for the field of diabetic neuropathy. 
For the first time, we demonstrated that a high-fat diet can potently modify neural symptoms by 
switching neuropathy phenotype from insensate to painful. These results shed light on why some 
diabetic patients experience painless symptoms while others present with painful symptoms. The 
knowledge gained from these findings provides a springboard for clinical investigations 
examining the relationship between diet composition and neuropathy development and 
phenotype. Furthermore, these studies suggest dietary intervention may be a useful therapeutic 
approach for preventing or reversing symptoms of diabetic neuropathy. 
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 Additionally, we report findings from three studies in which the novel high-fat/STZ-
induced type 1 diabetic model of diabetic neuropathy was used for the first time to investigate 
potential mechanisms (including oxidative stress, mitochondrial function, and neuronal insulin 
resistance) that may contribute to diet-induced changes in neural symptoms. Although many of 
the results were negative, these studies provide valuable guidance for future investigations to 
focus when searching for mechanisms underlying high-fat diet induced neuropathy and the 
relationship between dyslipidemia and neuropathy risk in diabetic patients.  
 Finally, we were the first to test the effects of exercise on neuronal insulin signaling in 
high-fat-fed mice. Exercise prevented deleterious effects on circulating glucose and insulin levels 
and insulin resistance in high-fat-fed mice. Results from this study reinforce the importance of 
exercise in preventing or reversing metabolic derangements and neural complications associated 
with diabetes. These data provide strong support to suggest clinicians should incorporate 
exercise intervention as a novel therapeutic to prevent and treat diabetic neuropathy. 
 Importantly, some key achievements from the work summarized in this dissertation 
advanced the diabetic neuropathy field. First, new animal models were developed to better 
parallel the human condition. These animal models included STZ-induced type 1 diabetes with 
dyslipidemia, pre-diabetes, and pre-diabetes with exercise intervention. In addition, novel 
approaches were utilized to explore mitochondrial dysfunction in diabetes. Specifically, 
mitochondrial respiration was measured in freshly isolated and undisrupted DRG and peripheral 
axons. Finally, experiments tested novel mechanisms associated with high-dietary fat that may 
underlie hyperalgesia, including inflammation and insulin resistance. In conclusion, this 
dissertation provides strong evidence for the influence of lifestyle factors including diet and 
physical activity on metabolic defects and neural complications associated with diabetes.    
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